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Background: Folate status of the U.S. population significantly improved after folic 
acid fortification of enriched cereal-grain products in 1998. Recent evidence suggests 
that the increased folate levels may have impacts on the risk of chronic disease. The 
kidneys are highly involved in folate metabolism. Reduced renal function may affect 
folate metabolism and play a role in the associations between folate and chronic 
disease.  
Objectives: The purpose of this study was to review key events regulating folate 
homeostasis along folate metabolic pathway. In addition, we examined the 
associations between folate intake and biomarker lev ls and the incidence of cancer, 
stroke and cardiovascular disease (CVD) and between folate biomarker levels and 
renal function among older adults in post-fortificat on years.  
Design: The Key Events Dose-Response Framework was used to r view key steps of 
folate metabolism. Data of adult participants of the National Health and Nutrition 




stroke and CVD were obtained from the linked Medicare nd mortality files. The 
associations between folate intake and biomarker lev ls and incidence of cancer, 
stroke and CVD, and the associations between estimated glomerular filtration rate 
(eGFR) and folate biomarkers, serum unmetabolized folic acid (UMFA) and plasma 
homocysteine levels were assessed using Cox proporti nal hazards regression models 
and multivariable regression models, respectively.  
 Results: The saturation of dihydrofolate reductase in the liv r is the determining 
point regulating the release of UMFA in circulation. Lower red blood cell (RBC) 
folate levels and intake of dietary folate equivalents were associated with a higher 
cancer incidence. Lower RBC folate and serum folate lev ls were associated with a 
higher stroke incidence. No significant associations between folate and CVD were 
observed. In addition, reduced renal function was associated with higher RBC folate 
and plasma homocysteine levels among men and women, and higher prevalence of 
UMFA in blood among women. 
Conclusion: High intake of folate may disturb folate metabolism by overwhelming 
folate regulation mechanisms. Folate may play a protective role against cancer and 
stroke even at high levels in post-fortification years. Reduced renal function may be 
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Chapter 1: Introduction 
 
Folate is a water-soluble B-complex vitamin, which can be found naturally in 
foods such as green leafy vegetables and citrus fruit . Folic acid is the synthetic and 
most oxidized form of this vitamin, which is the form added to fortified foods and to 
dietary supplements. Folic acid must be catalyzed by the enzyme dihydrofolate 
reductase (DHFR) to the reduced form before participating in intracellular reactions. 
High intake of folic acid could saturate the enzyme activity and bypass the reduction 
mechanism, which consequently lead to the release of unmetabolized folic acid 
(UMFA) in circulation. In the dissertation, folate was used as a collective term for 
naturally occurring folate and fortified/supplementd folic acid. However, due to their 
different chemical structures, they may have different impacts on health, thus will be 
discussed separately, when necessary.  
Since the human body does not have the ability to snthesize folate, a lack of 
dietary folate can lead to folate deficiency. This deficiency may result in many 
adverse health outcomes. The most notable one is neural tube defects (NTDs) in 
developing fetus. To reduce the incidence of NTDs, the U.S. instituted the mandate 
for folic acid fortification of enriched cereal-grain products to the level of 140 
µg/100g in 1998. This fortification program is estimated to supply on average an 
additional 100–200 µg folic acid per person per day b sed on the average American 
dietary pattern. The mandatory folic acid fortification program has successfully 
reduced the incidence of NTDs in newborns by almost 30% (2, 3). Fortification of 
enriched cereal-grain products with folic acid also significantly improved the 





has dropped to around 5% (4) and mean serum and red bloo  cell folate (RBC) levels 
are almost doubled in the post-fortification compared with those in the pre-
fortification years (Figure 1. 1).  
The population targeted by folic acid fortification f cereal-grain products is 
women of child bearing age. Older adults, however, have relatively higher levels of 
folate intake and biomarkers than other population groups (5). Safety concerns 
regarding high intake of folate among older adults ha been raised. High levels of 
folate biomarkers may disturb folate metabolism andresult in unintended health 
consequences. It is yet unclear what these relationsh ps may be because there are still 
some gaps in our knowledge of folate metabolism. Therefore, studies are needed to 
address these safety concerns and knowledge gaps.  
Altered folate intake either excess or deficient may fail regulation mechanisms 
and interrupt folate homeostasis, which could ultima ely lead to poor health 
conditions such as cancer and cardiovascular disease. Additionally, high intake of 
 
Figure 1. 1 Selected percentiles for pre- and post-fortification serum (A) and red 





folic acid may bypass the reduction mechanism and lea to the release of UMFA in 
blood. UMFA in the blood is reported to be prevalent among older adults as an 
outcome of high consumption of folic acid in post-fortification years (6). There is a 
speculation that UMFA could interrupt normal folate m tabolism (7-9) and lead to 
negative health outcomes such as cognitive impairment, d creased immune function 
and increased cancer risk (10-13). However, metabolism of UMFA and the potential 
effects on chronic disease have not been fully elucidated.  
In addition, high levels of folate intake and biomarkers may increase cancer 
risk, because high folate levels could promote the progression of pre-existing cancer 
by providing substrates for DNA replication in rapid cell division (14). In the U.S., 
approximately 11.3% of population exceeds the Tolerabl  Upper Intake Level (UL) 
of 1mg/day as an outcome of food fortification and supplement use (15). An 
ecological study in the U.S. have shown that an increase in cancer incidence 
coincided with population-wide increase in intake of folate (16). The safety concerns 
surrounding the high folate intake emphasize the needs of continued studies and 
carefully monitoring the effect of folic acid fortification on risk of cancer incidence. 
Additionally, folic acid fortification is hypothesized to contribute to the 
prevention of stroke. It was reported in an ecological study that a decline in stroke 
mortality paralleled the population-wide increase in serum folate and decrease in 
blood homocysteine concentrations in post-fortification years in the U.S. (17). 
However, it is still unclear how much of the decline i  stroke mortality is due to the 
decrease in incidence of stroke. Many factors, such as ospitalization rate of stroke 





impact stroke mortality (17, 18). Further study particularly longitudinal study is 
needed to elucidate the effects of folate on risk of stroke incidence in post-
fortification years. 
Finally, the kidneys are highly involved in maintaining folate homeostasis. 
Renal insufficiency may affect folate metabolism and this in turn may impact the risk 
of chronic disease. Currently, approximately 13% of the U.S. population are affected 
by chronic kidney disease (19). It is of great public health significance to examine the 
implication of renal insufficiency on folate biomarke s. 
In this dissertation, we first examined what we know of the key events and 
control points in the metabolic pathway of folate and then examined the effects of 
folate intake and biomarkers on the incidence of cancer, stroke and cardiovascular 
disease (CVD). Finally, we looked at the potential association between renal 
insufficiency and the levels of folate biomarkers. The specific aims of the study are:  
1) To review the key events in folate metabolic pathway that have major 
influences on folate metabolism and determining points regulating the 
release of UMFA using the Key Events Dose-Response Framework.   
2) To examine the associations between folate intake and biomarker levels 
and UMFA and the incidence of cancer by analyzing data of NHANES 
1999–2002 and its linked Medicare and mortality files. 
3) To examine the associations between folate intake and biomarker levels 
and the incidence of stroke and CVD by analyzing data of NHANES 





4) To examine the associations between renal function and folate biomarkers, 

























Chapter 2: Literature Review 
 
Folate metabolism 
Folate (used as a collective term for naturally occurring folate and 
fortified/supplemented folic acid) metabolism and homeostasis are regulated by a 
number of enzymes and transport systems along its me abolic pathway. The 
hydrolysis and absorption of folate in the small intestine, the uptake and metabolism 
of folate in the liver and the reabsorption of folate in the kidneys are key events in 
regulating folate homeostasis. Reduction of folic acid catalyzed by the enzyme 
dihydrofolate reductase (DHFR) in the liver is the determining point in folate 
metabolism leading to the release of UMFA in circulation. These regulation systems 
response to varied folate intake and maintain normal physiological folate levels. 
Altered folate either access or deficient folate intake may fail these regulation 
mechanisms and result in disturbance in folate homeostasis. High intake of folic acid 
can saturate the DHFR activity and lead to the release of UMFA into circulation. 
Detailed descriptions of key events and determining points of folate metabolic 
pathway are discussed in the first paper of Chapter 4 (page 23).   
 
Unmetabolized folic acid and disease  
UMFA in the blood is reported to be prevalent in approximately 38% of older 
adults (aged ≥ 60 years) as an outcome of high folic acid intake in post-fortification 
years, according to the data of NHANES 2001–2002 (6). It has been suggested that 
UMFA might disrupt folate metabolism by inhibiting folate-dependent enzymes, and 





the first step in folic acid metabolism, may inhibit purine and thymidine synthase and 
consequently interfere with DNA synthesis, which may trigger cancer process (7, 8). 
In addition, high folic acid levels may inhibit the methyl donor S-
Adenosylmethionine (SAM) synthesis by inhibiting methylenetetrahydrofolate 
reductase (MTHFR) and decreasing methylation reactions (9), which may lead to 
elevated homocysteine levels and hypomethylation of DNA.  
Though it is biologically plausible, the potential effect of UMFA on health is 
yet to be determined. Few epidemiological studies wre conducted to examine the 
associations between UMFA and health outcomes. A study by Selhub et al. in 2010 
showed that the presence of UMFA was positively associated with cognitive 
impairment in older adults (aged ≥ 60 years) (12). UMFA was also reported to be 
associated with decreased immune function among postmenopausal women (11). 
Given the fact that UMFA is prevalent in older adults and is hypothesized to be a risk 
factor for unintended health consequences, it is crucial to examine the effects of 
UMFA on risk of chronic disease.  
 
Folate and chronic disease 
Folate and cancer  
Folate functions as a coenzyme in single-carbon, methyl group transfers in the 
metabolism of nucleic acids. Folate is crucial for n mal DNA synthesis, repair and 
methylation. Folate is believed to have dual effects (promotion and inhibitory effects) 
on cancer development. A deficiency in folate may lead to an increase in cellular 





molecule and potentially leading to an increased risk of malignancy (20). 
Additionally, DNA methylation altered by folate deficiency was shown to up-regulate 
proto-oncogene expression and induce cancer (21). High folate levels, however, may 
promote the progression of pre-existing cancer by providing substrates for DNA 
replication in rapid cell division (14). 
It is hypothesized that high folate intake in the post-fortification years may 
increase cancer risk. Currently, about 11.3% of the U.S. population exceeds the 
Tolerable Upper Intake Level (UL) of 1mg/day as an outcome of food fortification 
and supplement use (15). In some countries with mandatory folic acid fortification, 
high intake of folate was hypothesized to contribute to an increase in incidence of 
colon cancer (16, 22). Manson, et al. in 2007 found that fortification of enriched 
cereal-grain products with folic acid coincided with an increase in the incidence rates 
of colorectal cancer in the U.S. and Canada (16). The authors found there were about 
four to six additional colorectal cancer cases per 100,000 individuals in post-
fortification years, and this increase in incidence could not be explained by the 
increased use of endoscopic examination. Similarly, n ecological study in Chile in 
2009 indicated that the incidence of colorectal cancer was significantly higher in post-
fortification years compared to pre-fortification years (22). In addition, a large, 
randomized, double blind placebo-controlled clinical tri l by Cole et al. reported that, 
long term and high dosage (1mg/day) of folic acid supplement significantly increased 
the risk of recurrence of advanced adenoma in the pati nts with a history of adenomas 





supplemental folic acid (≥ 400 µg/d) or from dietary folate intake (≥ 312 µg/d) was be 
associated with an increased risk of postmenopausal bre st cancer (23, 24).  
 
Folate and stroke and cardiovascular disease 
Folate is considered a preventive factor of atherosclerotic disease via its roles 
in lowering homocysteine levels. Homocysteine is a sulfur-containing amino acid 
which is broken down through either the methylation or the trans-sulfuration 
pathway, where folate serves as a methyl donor and vitamin B6 and vitamin B12 
function as coenzymes (25). Therefore, deficient folate, vitamin B6 and vitamin B12 
could lead to elevated homocysteine levels, which in turn may result in an increased 
risk of atherosclerotic disease including stroke. It has been reported that a 25% higher 
than normal circulating homocysteine concentration was associated with a 19% 
higher risk of stroke (26).  
High levels of folate intake and biomarker in post-fortification is considered 
to contribute to the prevention of stroke. It was reported in an ecological study that a 
decline in stroke mortality paralleled the population-wide increase in serum folate and 
decrease in blood homocysteine concentrations in post-fortification years in the U.S. 
(17). However, it is unclear how much of the decline i  stroke mortality is due to 
reduced incidence of stroke. Many factors, such as ospitalization rate of stroke and 
large public health programs promoting stroke prevention, may also impact stroke 
mortality (17, 18). Further studies are required to elucidate the effects of increase in 
folate intake and biomarker levels on risk of stroke incidence. In addition, the effect 





Findings of previous epidemiological studies suggest that folate itself could be an 
important protective factor for stroke (27, 28). It was reported that low serum folate 
levels were independently associated with a significantly higher risk of stroke among 
Canadians aged ≥ 65 years (28). Additionally, lower plasma folate levels were found 
to be independently associated with a significant higher risk of hemorrhagic stroke in 
the prospective study of the Northern Sweden Health and Disease Study Cohort (27). 
However, data are not available in post-fortification years in the U.S.  
 
Renal function and folate levels  
The kidneys are highly involved in maintaining folate homeostasis. A 
significant amount of folate are filtered daily and the proximal renal tubular 
reabsorption of folate prevents extensive urinary excr tion of folate (29). Folate 
receptors and other transporters such as cubilin and megalin located on renal tubule 
are found to be responsible for folate reabsorption (30). Expression of folate 
transporters was down-regulated and the uptake and utilization of folate by peripheral 
tissue and organs were decreased in rat models of chr ni  kidney disease (31). 
Absorption of folate by the small intestine was found to decrease in rat models of 
chronic kidney disease in another study (32). These changes in folate utilization and 
absorption may result in disturbance in homeostasis of folate.  
Renal insufficiency may affect folate metabolism and folate biomarker levels 
in blood and this in turn may have an impact on risk of chronic disease incidence. 
Few studies examined the folate biomarker levels among individuals with chronic 





patients with chronic kidney disease receiving dialysis (33). In other studies, 
however, decreased serum folate concentrations were obs rved in dialyzed patients 
(34, 35). Chronic kidney disease is an increasing healt  concern that affects about 
13% of the U.S. population (19). It is of public health importance to assess the impact 
of high intake levels of folate on biomarkers of folate among individuals with 
declining renal functions considering potential impact of altered folate levels on risk 





Chapter 3: Methods 
 
Data of adult participants in the National Health and Nutrition Examination 
Survey (NHANES) 1999–2002 were used to examine associati ns between folate 
intake and biomarkers and incidence of cancer, stroke and CVD, and between folate 
biomarker levels and renal function. Incidence of these chronic conditions was 
obtained from NHANES 1999–2002 linked Medicare and mortality files. To preserve 
the data integrity and privacy of survey participants, proposal of intended studies 
must be submitted for approval to the National Center for Health Statistics (NCHS). 
Additionally, NHANES 1999–2002 files and linked Medicare and mortality files are 
merged at the Research Data Center of NCHS (NCHS-RDC) to ensure that no 
identifying information is released. All analyses were also conducted at the RDC 
using SAS for windows (version 9.2, SAS Institute Inc, Cary, NC). All output of 
analyses was reviewed before their release to investigators. Prior to the initiation of 
the study, the studies that make up this dissertation obtained approval by the 
Institutional Review Board of the University of Maryland, College Park. 
 
The National Health and Nutrition Examination Survey (NHANES) 
Study design 
NHANES is a survey which monitors the nation’s health nd nutritional 
status. It is administered by the NCHS of the Centers for Disease Control and 
Prevention (CDC). Since 1999, the NHANES is continuously in the field and releases 





sampling design to select a nationally representative sample of the civilian, non-
institutionalized population of the United States. The NHANES sampling procedure 
consists of 4 stages. At the first stage, primary smpling units (PSUs) are selected. 
These PSUs are mostly single counties or groups of contiguous counties with 
probability proportional to a measure size (PPS). At the second stage, segments of the 
PSUs (generally city blocks or their equivalent) are sampled with PPS. At the third 
stage, households within each segment are randomly sampled, and individuals in 
selected households are sampled randomly within design d age-sex-race/ethnicity 
screening domains at the final stage (36). A sample of about 5,000 persons located in 
15 counties across the country is examined each year.  
Each sampled individual undergoes a household interview, which collects 
information on demographic and socioeconomic characte istics, health behaviors, and 
health status and supplement usage. This interview is followed by a visit to the 
Metabolic Examination Center (MEC) for laboratory tests and physical examinations, 
including anthropometric measurements, dietary intake and biochemical measures 
(37, 38). More details about NHANES and its methods can be found elsewhere (39).  
 
Assessment of diet and supplement 
Energy and nutrient intakes were estimated from a 24-hour dietary recall. The 
24-hour dietary recall is performed in the MEC by trained dietary interviewers in 
English or Spanish using computer-assisted dietary interview system. The 
information collected is total energy intake, nutrients, and non-nutrient food 





interview. For NHANES 1999–2000, the interview files were imported into the 
University of Texas Food Intake Analysis System (FIAS) for coding. FIAS version 
3.99 with the U.S. Department of Agriculture (USDA) 1994–1998 Survey Nutrient 
Database was used to process the NHANES 1999-2000 dietary data (39). In addition, 
for NHANES 2001–2002, FIAS (version 3.99) was used for coding dietary intakes 
for 2001. The Survey Net, a computer-assisted food coding and data management 
system developed by USDA, was used for coding dietary intakes for 2002. The 
USDA FNDDS (version 1.0), a database of foods, their nutrient values and weights 
for typical food portions, was used for processing the dietary intakes for NHANES 
2001–2002. 
Intake of dietary supplements was collected through the NHANES Dietary 
Supplement Questionnaire at the household interview. Participants were asked a 
series of questions about vitamin or mineral supplements use during the past 30 days. 
Detailed information is collected on name of manufacturer or distributor, 
consumption frequency, duration of use, and dosage (39). The average daily intake of 
folic acid from all dietary supplements was calculated based on the number of days of 
the consumption of supplements, the amounts taken per day, and the serving size 
from the product label.  
 
Assessment of socio-demographic and life-style characteristics  
Demographic information, including age, gender, self-identified race/ethnicity 
and educational level, were collected at the household interview. Race/ethnicity was 





Hispanic black and other race (including Multi-Racial). In this study, three 
race/ethnicity categories were used: non-Hispanic white, non-Hispanic black and 
other (Mexican American, other Hispanic and other races). Educational attainment 
was categorized as less than high school, high school graduate (received a high school 
or high school equivalency diploma) and greater than igh school.  
Data on lifestyle, including physical activity, alcohol consumption and 
cigarette smoking, were obtained through interviewer-administered questionnaires. 
Physical activity level was self-reported as sedentary, light, and moderate or higher. 
Alcohol consumption was assessed as grams per day fom the 24-hour dietary recall. 
Cigarette smoking status was categorized as never, former and current. A nonsmoker 
was defined as a participant who had never smoked ≥ 100 cigarettes during his/ her 
life; a former smoker was defined as a participant who had smoked ≥ 100 cigarettes 
and was not smoking at the time of the interview; and  current smoker was defined 
as a participant who had smoked ≥ 100 cigarettes and was smoking at the time of 
interview. Body measurement was conducted in the MEC by trained health 
technicians. Height was measured using fixed stadiometer with a vertical backboard 
and a moveable headboard. Height was measured on a T ledo digital scale (40). Body 
mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared (kg/m2).  
 
Biochemical measurements  
Serum folate and red blood cell folate concentrations were measured with the 





Hercules, CA. UMFA in NHANES 1999–2002 participants aged 60 years and over 
was measured using a revised affinity/ HPLC method with electrochemical 
(coulometric) detection. The lower limit of detection for UMFA was 0.18 nmol/L and 
values below the level of detection were set to zer. Serum creatinine was measured 
based on the Jaffe reaction. Serum creatinine measur ments of participants of 
NHANES 1999–2000 were recalibrated to standardized cr atinine measurements 
(creatinine measurements obtained at the Cleveland Cli ic Research Laboratory, 
Cleveland, Ohio) using the equation: standard creatinine = 0.147 + 1.013 × un-
calibrated serum creatinine (mg/dL) (41). Serum alanine aminotransferase (ALT) was 
measured using an enzymatic rate method (42). Plasma ho ocysteine was measured 
by using a fluorescence polarization immunoassay regent set from Abbott 
homocysteine assay, Abbott Park, IL. Complete details and documentation for each of 
these methods are described elsewhere (43, 44).  
 
The Medicare and mortality data linkage 
NCHS has linked data of participants of NHANES 1999–2002 to Medicare 
enrollment and claim records collected from the Centers for Medicare and Medicaid 
Services (CMS). Medicare enrollment and claims dataare available for NHANES 
respondents who agreed to provide personal identification data to NCHS, and for 
whom NCHS was able to match personal data with Medicare administrative records 
between 2005 and 2007 (45). The Medicare Chronic Conditi n Summary File is a 
summary of clinical information extracted from the NCHS-CMS linked data for the 





Cancer (breast, colorectal, prostate, lung and endometrial cancers), stroke 
(stroke/transient ischemic attack) and CVD (acute myocardial infarction, heart 
failure, ischemic heart disease, and stroke/transient ischemic attack) were identified 
using NCHS designed algorithms of disease codes from Medicare claim records. 
These are ICD-9 (International Classification of Disease), CPT-4 (Current Procedure 
Terminology) and/or HCPCS (Healthcare Common Procedure Coding System) codes. 
More details about algorithms of codes can be found in Appendix B of the NCHS-
CMS Medicare Chronic Condition Summary File Data Dictionary (46).  
Data of NHANES 1999–2002 participants are also linked to the National 
Death Index (NDI) through December 31, 2006. Mortality ascertainment is based 
upon the probabilistic match between the NHANES and National Death Index (NDI) 
death certificate records (47). The Linked Mortality Restricted-use File provides 
follow-up data on mortality from the date of survey participation through December 
31, 2006. The date of death, underlying and multiple causes of death in ICD-10 are 
recorded in the Linked Mortality Restricted-use File. More details about the Mortality 
File can be found elsewhere (48).  
 
Cancer, stroke and CVD cases ascertainment  
We used data of NHANES 1999–2002 participants aged 57 years and above 
to capture all individuals who would potentially reach the age of Medicare eligibility 
by 2005 to 2007 (Medicare has age-based entitlement at 65 years of age). Cancer, 
stroke and CVD cases of this population were identifi d from the NHANES Linked 





participants who died before 2005, cancer, stroke and CVD cases were identified 
from the Linked Mortality Restricted-use File using either underlying or multiple 
causes of death. Date of death from cancer/stroke/CVD was used as the date of 
disease first occurrence.  
 
 Assessment of renal function 
Estimated glomerular filtration rate (eGFR) was used to assess renal function. 
eGFR, normalized to 1.73 m2 of body surface, was estimated using the Chronic 
Kidney Disease Epidemiology Collaboration ( CKD-EPI) formula (49): eGFR 
=141×min (SCr/k, 1)α × max (SCr/k, 1)-1.209 ×0.993Age × [1.018 if women] × [1.159 if 
Black]. ‘SCr’ represents serum creatinine (mg/dL), ‘k’ is 0.7 for women and 0.9 for 
men, and ‘α’ is -0.329 for women and -0.411 for men (49). Indivi uals with eGFR 
less than 60 mL/min/1.73 m2 and those with eGFR between 60 and 90 mL/min/1.73 
m2 were defined as having reduced renal function and mil ly reduced renal function, 
respectively (50). Individuals were categorized based on their CKD-EPI eGFR values 
in three categories as < 60, 60–90 and ≥ 90 mL/min/1.73 m2.  
 
Statistical methods 
Studies of associations between folate levels and risks of cancer, stroke and CVD 
UMFA measurements were categorized into detectable UMFA (UMFA+) and 
undetectable UMFA (UMFA-) categories. ANOVA for continuous variables and Chi-
squared tests for categorical variables were used to xamine possible associations 





and dietary folate equivalents and potential confouders. The second quartile, which 
includes recommended dietary allowance of folate, was used as the reference group in 
the regression models. 
Cox proportional hazards regression models were used to xamine hazard 
ratios (HR) and 95% confidence intervals (95% CI) for incidence of cancer by 
quartiles of folate intake and blood biomarkers. Follow-up person-years of each 
participant were estimated from baseline interview to the endpoint (the earliest 
occurrence of cancer/stroke/CVD), or death, or the end of the follow-up period 
(December 31, 2007), whichever came first. To examine the association between 
folate and cancer, we conducted a multivariable Coxpr portional hazards regression 
model for each of the folate intake and biomarker variables of interest. These 
confounders included age, gender, race/ethnicity, educational attainment, energy 
intake, BMI, physical activity, smoking status and alcohol intake. We also tested for 
possible linear association between of folate intake nd biomarkers and the incidence 
of overall cancer using linear regression models. Serum folate, RBC folate, intakes of 
dietary folate, folic acid and dietary folate equivalents were logarithmically 
transformed, because these five folate exposure variables were not normally 
distributed. 
 In addition, we used a similar approach to assess the associations between 
folate levels and the incidence of stroke and CVD. We conducted a multivariable-
adjusted Cox proportional hazards regression model f r ach of the folate intake and 
biomarker variables of interest adjusted for potential confounders. These confounders 





physical activity, BMI, total energy intake, serum total cholesterol and high-density 
lipoprotein (HDL) and cholesterol. For the independt association between serum 
and RBC folate and stroke and CVD, plasma homocysteine was included as a 
cofounder in the regression models. We also tested possible linear associations 
between folate intake and biomarkers levels and the incidence of stroke and CVD 
using linear regression models. As indicated above, folate intake and biomarkers 
variables were logarithmically transformed. In all studies, we evaluate the 
proportional hazards assumption that there is no significant interaction between 
predictors and follow-up time; and no violation to this rule was found. 
Additionally, in all these studies, data was treated as simple random sampling 
data and sample weight was not incorporated in data analyses. Due to ineligibility for 
the linkage to Medicare and mortality files, not all of data of NHANES 1999–2002 
participants were included and analyzed. Participants included in our study were not 
proportionally selected within NHANES 1999–2002 designated age-sex-
race/ethnicity screening subdomains. Therefore, the original survey weight is not 
applicable for analyses of the data of this subpopulation. Adjustment of sample 
weight for incomplete linkage and non-matches is necessary for the purpose of 
generating unbiased national estimate. However, our sample was only a subset of the 
population of interest and was not representative of age, gender or race/ethnicity. 
Therefore, data was treated as simple random sampling data as described above. 
Furthermore, there were no significant associations between folate intake and 






Study of associations between renal function and folate biomarker levels 
Data analyses were performed using SAS for windows (version 9.2, SAS 
Institute Inc, Cary, NC) and SAS-callable SUDAAN (version 10.1; Research Triangle 
Institute, Research Triangle Park, NC). Analyses were conducted incorporating the 
four-year sampling weight to account for complex sampling design (51). Data of 
participants were classified into three categories according to their eGFR values (< 
60, 60–90 and ≥ 90 mL/min/1.73 m2). UMFA measurements were categorized into 
detectable UMFA (UMFA+) and undetectable UMFA (UMFA-) categories. Variables 
that were not normally distributed (with a skewness > 4) were log-transformed before 
group comparison and regression analyses. All testswere stratified by gender (men 
and women), because there was a statistically significa t interaction between gender 
and eGFR when testing relations between eGFR and blood folate biomarkers of 
interest. Statistical significance was set at p < 0.05. The category eGFR ≥ 90 
mL/min/1.73 m2 was set as the reference group in all an lyses.  
Dunnett's test and Chi-squared tests were used to compare group means of 
continuous variables and group percentages of categorical variables, respectively. 
Serum folate, RBC folate and plasma homocysteine lev ls were assessed in relation 
to eGFR using multivariable linear regression models. Regression models for serum 
folate and RBC folate were adjusted for age, gender, race/ethnicity, smoking status, 
alcohol intake, BMI, physical activity, educational attainment and intake of dietary 
folate equivalents. Regression model for plasma homocysteine was additionally 
adjusted for intake of vitamin B12. Test for trend was performed using linear 





we examined associations between UMFA and eGFR categories. Odds ratios (OR) 
for the presence of UMFA in the blood and 95% confidence intervals (95% CI) were 
estimated based on eGFR categories using multivariable logistic regression models. 
Logistic regression models were adjusted confounders, including age, gender, 
race/ethnicity, smoking status, alcohol intake, BMI, physical activity, educational 







Chapter 4: Results  
 





Folate is a vitamin that plays a role as a cofactor and coenzyme in many 
essential reactions. These essential reactions include nucleic acid synthesis and 
numerous methyl- transferase reactions such as DNA methylation and amino acid 
metabolism. These are all interrelated reactions and any change in folate homeostasis 
could affect other reactions (Figure 4. 1). Mandatory folic acid fortification of 
enriched cereal-grain products implemented in 1998 in the U.S. has been shown to be 
somewhat effective in reducing neural tube defects (NTD) in newborns. However, 
studies show that it is not uncommon for individuals in the U.S. to exceed intake of 
the Tolerable Upper Intake Level (UL) of 1mg/day, as an outcome of food 
fortification and supplement use (5, 15). Also, the appearance of unmetabolized folic 
acid (UMFA) in blood circulation is now quite prevalent in the general population 
(52). This has led to concern that UMFA may disturb cellular folate uptake and 
normal intracellular folate metabolism which ultimately may lead to negative health 
outcomes (10-12, 53). 
A potential negative outcome of high folic acid intake is the masking of 
vitamin B12 deficiency among older adults which may lead to cognitive impairment 
(12, 54). Another concern is that high folic acid intake may increase the risk of 
recurrence of colorectal adenoma among individuals with history of adenoma (53). 





makes it crucial to explore ways to identify the mini um effective intake of folic acid 
that is required to prevent NTDs while minimizing the risk of negative outcomes due 
to excessive intake among vulnerable populations.   
 
As a step towards that end, we used the framework known as the Key Events 
Dose-Response Framework (KEDRF), a component of the In ernational Life Science 
Institute’s (ILSI) Global Threshold Project (55), to review what is known about each 
of the major key events, dose-response characteristics and homeostatic mechanisms 
along the folate metabolism pathway (Figure 4. 2 and Figure 4. 3). This analytical 
approach has been applied in a case study with vitamin A (56) and found to be a 
useful tool in integrating knowledge and identifying research gaps. Since UMFA is a 
relatively new phenomenon, we examine in this paper its appearance in serum as our 
outcome of concern, and review the major steps or key events in the metabolic 
pathway that lead to it. 
In this review, we identify control points which are the mechanisms that help 
maintain a normal physiological environment. The capacity of such mechanisms to 
keep homeostatic balance is likely to influence the ov rall dose-response relationship 
between total folate intake and UMFA (56). Certain co trol points may play an 
especially critical role in a given pathway; and if the outcome of these control points 
greatly influence the likelihood of the ultimate effect of concern, such as the 
appearance of serum UMFA; then such control points are identified as determining 
events (55). In addition, we identify gaps in our knowledge of folate metabolism that 





We use folate as a collective term for naturally-occurring folate and 
fortified/supplemented folic acid; however, due to their different chemical structure, 
they may undergo different biochemical reactions in certain metabolic steps and thus 
will be discussed separately, when necessary.  
 
Functions and adverse effects associated with folate 
Folate functions as a coenzyme in single-carbon, methyl group transfers in the 
metabolism of nucleic acids and amino acids. Folate is crucial for normal DNA 
synthesis and is needed for pyrimidine and purine bosynthesis (Figure 4. 1). 
Pyrimidine nucleotide biosynthesis requires folate co-enzyme in the conversion of 
deoxyuridylic acid to thymidylic acid. Folate is believed to have dual effects 
(promotion and inhibitory effects) on cancer development. One of the hypothesis is 
that a deficiency in folate may lead to an increase in cellular uracil to thymidine ratio, 
thus, misincorporating uracil into DNA, destabilizing DNA molecule and potentially 
leading to an increased risk of malignancy (20). Additionally, cytosine methylation 
altered by folate deficiency was shown to up-regulate proto-oncogene expression and 
induce cancer (21). Several prospective studies have showed an inverse association 
between folate and cancer (57-62).  
In contrast, results from limited studies showed a positive association between 
high folate intakes and cancer. Such an association between folate intake and 
colorectal cancer was hypothesized from the results of two ecological studies (16, 
22). However, results of epidemiological studies have been inconsistent (63). Animal 





of folate on the development and progression of colorectal cancer (64) and on the 
protection against colorectal cancer (65). Whether and how folate may exert these 
dual effects on colorectal carcinogenesis appears to depend on the timing and dose of 
the folate intervention (14, 66). The mechanism lies in the essential role of folate in 
DNA synthesis and the biological methylation reactions  
Either deficient or excessive folate could also be related to cognitive 
dysfunctions in the presence of low vitamin B-12. Folate and vitamin B-12 are 
essential in the conversion of homocysteine to methionine, the precursor of S-
adenosyl methionine (SAM). SAM is a methyl donor to a wide range of reactions 
involving DNA, protein and lipids. Folate acts as the methyl donor where 5-
methyltetrahydrofolate (5-MTHF) is converted to tetrahydrofolate (THF) and the 
methyl group is donated to homocysteine to form methionine (Figure 4. 1). The 
deficiency of folate and vitamin B12 is associated with reduced cellular SAM and 
elevated homocysteine levels (67, 68), potential disrupted formation of myelin (which 
is essential for the proper functioning of the nervous system) (69), as well as 
hindrance of DNA synthesis and cell division (20, 7). Additionally, vitamin B12 is 
the only acceptor of the methyl group from 5-MTHF and homocysteine is the only 
acceptor of methyl-B12. Thus, a deficiency in vitamin B12 can generate a large pool 
of methyl-THF that is unable to undergo reactions ad will mimic folate deficiency 
and accumulate homocysteine. The only way for the 5-MTHF to be recycled to THF, 
and thus to participate in DNA biosynthesis and cell division, is through the vitamin 
B12 - dependent enzyme methionine synthase. In its absence, cellular folate will 





nucleotides will be synthesized and the hematological picture of megaloblastic 
anemia will be normalized but not the neurological symptoms associated with vitamin 
B12. This may lead to masking of vitamin B12 deficiency and to the progression of 
potentially irreversible neurological symptoms (dementia, paresthesia and ataxia) 
(71).  
 
Uptake from lumen into enterocyte 
Digestion in lumen 
Most naturally occurring folates are polyglutamate derivatives. These are 
hydrolyzed to monoglutamates on the surface of intestinal mucosa by the hydrolase 
enzyme glutamate carboxypeptidase II (GCP II) prior to absorption into the intestinal 
cells. Folic acid is a monoglutamate, so hydrolysis is not necessary for its absorption. 
GCP II is located on the human jejunum brush border and is sufficient to 
hydrolyze dietary folate intake (10 cm proximal jejunum in humans contains GCPII 
to hydrolyze 200 µg folate) (72). There is currently o evidence to show that 
excessive intake of folate will saturate GCP II. There appears to be adaptive up-
regulation of the enzyme in case of folate deficieny (73), but the molecular 
mechanism and threshold dose that would trigger this up-regulation has not been 
identified. It is unclear whether GCP II is down-regulated in the presence of excess 
folate. 
Thus, GCP II is not an important control point, although it is adaptively 
regulated. Reisenauer et al. (74) reported that the rate of hydrolysis of polyglutamyl 





monoglutamyl folate transportation into intestinal ce ls, which suggests that the 
transport of the monoglutamate end-product is the rat -limiting step in the process of 
dietary folate absorption. 
 
Transportation into intestinal cells  
 Folate monoglutamates are hydrophilic anionic molecules and at physiologic 
concentrations of luminal folate (<10umol/L), the uptake mainly occurs via a carrier-
mediated process (75). In this process, two proteins; the Reduced Folate Carrier (RFC) 
and the Proton-Coupled Folate Transporter (PCFT), are responsible for intestinal 
folate uptake in the proximal jejunum and duodenum (76). This process requires 
energy and is dependent on acidic pH. However, at high amounts of folic acid, 
passive diffusion through nonsaturable mechanism does occur (75).  
RFC is an integral membrane protein and is ubiquitously expressed in tissues 
to play a central role in tissue folate homeostasis (77). RFC has a high affinity for 
reduced folate and a low affinity for folic acid (78). PCFT prefers oxidized folate 
such as folic acid to reduced folates as substrates, lthough affinities for all folate 
analogs for PCFT are high at micromolar range (76, 79). Both RFC and PCFT are 
inversely responsive to folate concentration, so that uptake is reduced when dietary 
folate intake is high and increased when intake is low (80, 81). In animal and in vitro 
studies, both mRNA and RFC protein expression increased in a folate deficient 
environment (73, 82). Similarly, PCFT mRNA levels increased about 13-fold in the 
proximal small intestine of mice that were fed a folate-deficient diet, as compared to 





Conversely, down-regulation of RFC and PCFT occurs under conditions of 
over-supplementation. It has been reported that levels of 100 µmol folic acid/L in 
culture media lead to significantly reduced folic acid uptake in Caco-2 cells, as well 
as a significant decrease in RFC and PCFT mRNA levels (84). Similarly, in a rat 
model, acute folate over supplementation led to significant decrease in intestinal 
folate uptake by down-regulating the expressions of RFC and PCFT (85). The 
regulation of intestinal uptake appears to be mediat  by transcriptional regulatory 
mechanisms. It is unclear what amounts of folate and folic acid in humans will 
saturate the carrier proteins leading to passive diffusion. 
In summary, the carrier-mediated intestinal process is important for 
maintaining normal physiological folate levels and meeting metabolic requirements. 
Uptake from the lumen into the enterocyte is a homeostatically regulated event, and is 
a control point influencing folate homeostasis. Folate deficiency and over 
supplementation lead to a respective up-regulation and down-regulation of folate 
transporter molecules, as evidenced by respective incr ases or decreases in their 
mRNA and protein levels. However, at high levels of folic acid intake, passive 
diffusion may occur and folic acid enters the cells. The specific mechanisms that 
dictate how folate levels affect the mRNA and protein l vels of folate transporters are 
not clear. Also, the threshold for folate and folic acid absorption is unclear. 
 
Intestinal intracellular metabolism and distributio n  
Folate monoglutamate and folic acid are transported into intestinal cells where 





enterocytes, intracellular metabolism such as reduction, methylation and 
polyglutamate synthesis takes place. Some of the folic acid will undergo an additional 
reduction process to dihydrofolate (DHF) and THF catalyzed by dihydrofolate 
reductase (DHFR). THF will be methylated to 5-MTHF before entering the portal 
circulation (86, 87). Some of the 5-MTHF will be stored in cells by having glutamate 
residues added to the molecules to increase their siz  and hence prevent them from 
leaving the cells (88).  
The capacity of DHFR to reduce folic acid in intestinal cells is low and some 
of the folic acid in its unmetabolized form will ent r the portal circulation. 
Additionally, DHF is a potent inhibitor of methyl tetrahydrofolate reductase (MTHFR) 
(9); therefore, high concentrations of folic acid could inhibit the formation of 5-
MTHF and lead to a decrease in methionine and SAM (methyl donor) synthesis. In 
those with poor vitamin B-12 status, methionine synthesis is already compromised, so 
this mechanism could exacerbate the methyl group deficiency. To our knowledge, no 
data is available to indicate the amount of folic acid that can saturate DHFR in 
humans. 
After intracellular modifications, monoglutamylfolates, mainly 5-MTHF and 
unmetabolized folic acid (UMFA) are transported through the enterocyte basolateral 
membrane into portal circulation. The efflux is transported via a carrier-mediated and 
active anion exchange mechanism (89). Similar to the brush-border membrane, RFC 
and PCFT are located at the basolateral membrane responsible for trans-membrane 
transport (90). However, compared with the brush-border membrane transport system, 





intracellular neutral environment (89, 90) and PCFT is believed to be the major 
carrier at this level (91).  
In this key event, monoglutamate and folic acid are biotransformed or leave 
the cells intact. The DHFR which catalyzes the reduction of folic acid is a control 
point. DHFR has low capacity and so folic acid may exit the cells for the portal 
circulation in its unmetabolized form.  
 
Hepatic metabolism and distribution  
Enterohepatic circulation of folate 
Liver is the major site for folate storage and processing. Folate is taken up 
from the portal circulation and enters the liver in the form of monoglutamate (THF 
and primarily 5-MTHF) and UMFA. The transport process is saturable energy-
dependent at low folate concentration, while at higher concentration of folate (up to 
20 µmol/L), the uptake is not saturable (92). Once tak n up by liver, more than 97% 
of 5-MTHF is rapidly cleared into bile. While 15-20% of THF is retained in liver 
predominately in the form of polyglutamate for storage (93). The liver contains half 
of the body’s folate. Though a substantial fraction of the folate is shunted to bile, 
most of the folate in bile is reabsorbed in the intstine via enterohepatic circulation 
(94). 
 
Folate metabolism in liver 
Monoglutamate and folic acid are taken up by the liv r primarily by PCFT. 





methylation and polyglutamate formation (76). Similarly to what occurs in the 
enterocyte, DHFR is also the enzyme responsible for reduction of folic acid in the 
hepatocyte, and its activity is a major control point in the hepatic metabolism of folic 
acid. Compared to rats, human DHFR activity is quite low (95). It takes about an hour 
to convert 400 µg of folic acid to the reduced form, while the time to convert 5 mg 
could take up to 12 hours (96). The limited reduction capacity of DHFR results in the 
appearance of UMFA in plasma and urine. Bailey and Ayling (2009) reported that a 
concentration of about 331 µg of folic acid in human liver could saturate available 
DHFR (96). They suggested that human liver is the fundamental cause for the 
appearance of UMFA in blood circulation. The authors reported that DHFR activity is 
low and quite variable in human samples and suggested that the plasma concentration 
of UMFA and possibly DHF will vary between individuals according to their DHFR 
activity. Therefore, this control point which may become saturated by excessive 
intake of folic acid is a determining event as it does not fully control the release of 
UMFA in blood circulation. 
The appearance of UMFA in serum may also be affected by genetic 
polymorphism. DHFR polymorphism which includes the deletion of a specific 19-bp 
region of DHFR gene was associated with increased gene expression (97, 98). This 
could lead to greater one carbon metabolism in favor of DNA synthesis and at the 
expense of methyl supply. This polymorphism was implicated in increased risk of 
cancer (97) and decreased risk of neural tube defect (98). In contrast, data from the 





higher UMFA (99). Further studies are needed to clarify the role of this 
polymorphism in humans.  
Effort was made to determine the threshold at which UMFA starts to appear in 
blood circulation. Kelly and colleagues reported that oral folic acid intakes of 266 
µg/meal resulted in UMFA in the serum, while no UMFA was observed in serum of 
individuals taking less than 200µg/meal (100). Similarly, Sweeney et al. detected 
UMFA in serum of folic acid replete individuals after an oral dose of 200 µg per meal 
administered twice a day for 7 days (101). The increased appearance of serum folic 
acid after the second 200 µg per meal dose of folic acid indicate that accumulation 
may occur over time. In the Framingham Offspring Study serum folic acid was 
measured before and after mandatory folic acid fortifica ion and the results show that 
exposure to fortification significantly increased circulating concentrations of folic 
acid, total plasma folate, and 5MTHF among both supplement and non-supplement 
users (102).  
In this key event, most of the 5-MTHF is circulated back to the intestine via 
enterohepatic circulation. Folic acid is reduced by DHFR, however, that enzyme has 
low activity and, intake of 200 µg/meal may lead to the appearance of UMFA in 
circulation. Thus this event- conversion of folic acid by DHFR to its reduced form- 
may be responsible for the appearance of UMFA in blood circulation and, is 





Kidney folate reabsorption 
Folate is transported in blood primarily as monoglutamate in three forms: free 
folate, folate bound to folate binding protein and folate bound to albumin, all of 
which can be filtered by human kidney (29).  
Filtered folates are reabsorbed back to circulation fr m the proximal tubule 
cells and folates not reabsorbed are finally excreted in urine. Therefore, the 
homeostatic level of folate in human body is regulated by the reabsorption of filtered 
folate in the proximal tubule cells. The reabsorption is mediated mainly by three types 
of receptors; folate receptors (FR), megalin and cubilin, which are all located in the 
kidney proximal tubule epithelial cells. Of these receptors, FR is the most important 
one and has high affinity for a number of folate comp unds including folic acid (103). 
The expression of FR is regulated by extracellular folate concentration; however, 
results of studies are somewhat contradictory depending on experimental model used. 
In vitro studies show that FR expression on renal epith lial cells was down-regulated 
with over-supplementation of folic acid at a level of 100 µmol/L culture medium (84), 
and up-regulated under low-folate conditions (104, 105). In contrast, a low-folate diet 
led to down-regulation of FRs in studies on mice and rats (106, 107). This down-
regulation is suspected to occur due to proteolysis of the membrane anchor for the 
receptors which become unsaturated as a consequence of the diminished folate 
concentration in the glomerular filtrate (76). Once folate is taken up by the receptors, 
the reabsorbed filtered folate crosses the basolatera  membrane to blood circulation 






Renal tubular reabsorption plays a pivotal role in maintaining folate 
homeostasis by reabsorbing the filtered folate. However, the regulation of tubular 
folate uptake remains to be established under both excess and deficient folate and 
folic acid intake.  
 
Tissue uptake, storage and intracellular metabolism of folate 
Folate uptake at peripheral tissues occurs via folate receptor FR and 
membrane carrier RFC (76) and these are overexpressed in the presence of folate 
deficiency (107, 109-111). Of concern, is that UMFA could compete with 5MTHF 
for carrier protein and binding protein with special oncern for folate metabolism in 
the brain (112). This mechanism, however, has yet to be demonstrated.  
Once monoglutamates enter mammalian cells they are rapidly modified for 
storage by the addition of several glutamate residues to form long side chains in order 
to trap the folates within the cells. Polyglutamate synthetase plays a regulatory role in 
maintaining a relatively constant tissue folate concentration by increasing the 
polyglutamate chain length in periods of folate defici ncy (113). It is suggested that 
modest increases in cellular concentrations of folate will activate the folate-dependent 
reactions while large increases may inhibit those reactions and their related enzymes 
(112, 113). 
Little is known about intracellular effects of folic acid. Some reports indicate 
that folic acid might disrupt folate metabolism by disturbing the balance of folate and 
several folate-dependent enzymes, where elevated folic acid could act as inhibitor. 





and thymidine synthase and consequently interfere with DNA synthesis (7, 8). 
Additionally, high folic acid also can inhibit SAM (methyl donor) synthesis by 
inhibiting MTHFR (9) and decreasing methylation reactions. 
 One of the theories put forward is that excess folic acid among individuals 
with low vitamin B12 may allow cell division in bone marrow to proceed, as it is 
independent of methionine synthesis, but these growing cells could place increased 
demand for methyl group further depleting available m thyl groups and worsening 
the impact on non-proliferating cells of the nervous system (112, 114). 
 Tissue uptake and storage of folate is a key event of folate metabolic 
pathway. However, knowledge of the regulatory mechanisms within cells is limited 
and at this time several theories have been put forward to explain potential impact of 
excess folic acid on health outcome, however, these av  yet to be determined.  
 
Discussion 
The Key Events Dose-Response Framework developed by ILSI, is an 
interesting and flexible analytical approach to reviewing nutrient metabolism because 
it can be used to integrate research findings within key events and channel this 
information towards an endpoint of interest. In this paper we use the release of 
UMFA in blood circulation as our endpoint. There is no evidence that folic acid in 
circulation occurs naturally, so the appearance of folic acid in the blood indicates that 
excess folic acid intake has occurred due to supplement use and/or fortified food.  
Folate is regulated within each of the key events. The intestine, liver and 





these key events, however, limited information is avail ble on folate threshold and 
homeostatic regulation. Additionally, little is known about intracellular effects of 
folic acid. The determining event in folate metabolism leading to the release of 
UMFA in serum is the reduction of folic acid to DHF and THF by the liver enzyme 
DHFR. Excessive intake of folic acid can saturate DHFR. Once the saturation 
threshold is reached in the liver, UMFA is released into circulation. Results of studies 
indicate that the lowest amount of folic acid intake that resulted in serum UMFA is an 
oral dose of 200 µg. There is also some indication that folic acid accumulation occurs 
over time. It is currently not uncommon to detect UMFA in blood especially since 
folic acid is present in supplement and fortified food. Intakes exceeding the Tolerable 
Upper Intake Level (UL) of 1mg/day has been reported (5, 15) and may potentially 
affect vulnerable populations such as children and older adults.  
Results of epidemiological studies have shown associati ns between UMFA 
and negative health outcomes such as cognitive dysfunction, cancer and stroke. 
Several theories were put forward to explain the mechanism by which UMFA could 
lead to negative outcomes. One theory put forward is that high folic acid supply DHF 
and THF providing substrate to proliferating cells at the expense of methyl reactions. 
The impact of these changes includes masking of potentially irreversible symptoms of 
cognitive dysfunction and providing substrate to cancer cells. Alternatively, studies 
have shown that great increase in total cellular folate may inhibit folate-dependent 
reactions. Therefore, the question still remains as to whether it is UMFA, increase in 





Results of studies indicate that the appearance of UMFA in serum varies by 
individuals. This may be due to genetic makeup and possibly to the presence of 
DHFR polymorphism. Further studies are needed to clarify the role of this 
polymorphism in humans and to identify other potential genetic effects on folate 
metabolism as a consequence of excessive folate intake.  
Limited knowledge of the regulation mechanisms and threshold for some key 
events limit our ability to quantitatively characteriz  the dose-effect relationship and 
yet it is critical to do so at this time in light of the petition submitted to FDA by the 
Centers for Disease Control and Prevention and other rganizations to extend food 
fortification to corn masa flour, a basic ingredient in many foods, such as corn 
tortillas, that are predominantly, but not exclusively, consumed by the Hispanic 
population. Compared with other race-ethnicities, Hi panic women have higher rates 
of infants born with NTDs and lower total folic acid intake (115). This increase in 
folic acid in the food supply, however, may negatively affect vulnerable populations 
including Hispanic older adults. 
Finally, folate is involved in many reactions that could affect DNA synthesis 
and amino acid metabolism. Any change such as deficiency or excess could 
potentially affect a cascade of responses. It would, therefore, be of interest to apply 
KEDRF to some of the other endpoints in folate metabolism to examine the impact of 













B12, vitamin B-12; DHFR, dihydrofolate reductase; CH3, methyl group; CpG 
cytosine-guanine dinucleotide sequence; MTHFR, methyl netetrahydrofolate 





























































Figure 4. 2 Key Events and control points in the metabolic pathway of folate 
 
 
UPTAKE FROM LUMEN INTO INTESTINAL CELLS  
• Highly efficient hydrolysis of folate to monoglutamte 
• Folic acid/monoglutamate taken up via carrier mediat  
absorption.  
• High levels of folic acid saturate carrier proteins and passive 




• Folic acid is reduced to DHF and THF by DHFR  
• THF is converted to 5-MTHF, and released to portal circulation  
• Excess folic acid saturates DHFR and released in portal circulation as unmetabolized 
folic acid 
 
HEPATIC METABOLISM  
• 5-MTHF, THF and folic acid are taken up by saturable means into liver. Folic acid is 
reduced to DHF and THF by DHFR (200-266 µg folic acid per/meal may saturate 
DHFR). 
• Excess folic acid saturates DHFR and unmetabolized folic acid is released into blood 
circulation 
• Some of the THF is synthesized to polyglutamate and stored. 
• 97% of 5-MTHF is cleared into bile and reabsorbed via enterohepatic circulation 
 
TISSUE UPTAKE 






• Filtered folates are reabsorbed from 
proximal tubules, mediated by receptors.  
• Homeostatic regulation. Folate is released 

































B) Associations between folate levels and cancer morbidity among 




Background: Mandatory folic acid fortification of enriched cereal-grain products in 
the U.S. has significantly improved the folate status of the population and decreased 
the incidence of neural tube defects (NTDs). However, safety concerns have been 
raised that excess consumption of folic acid and high blood folate biomarkers 
detected in adults in the U.S. may increase the risk of cancer.  
Objective: The purpose of this study was to examine associations between folate 
intake, folate biomarkers levels, and the presence of unmetabolized serum folic acid 
(UMFA) and the incidence of cancer in a prospective study of older adults in post-
fortification years. 
Design: Data from participants of the National Health and Nutrition Examination 
Survey (NHANES) 1999–2002, aged ≥ 57 years were used as the baseline data for 
this study. Overall incidence of cancer (colorectal, breast, prostate, lung and 
endometrial cancers) was estimated from the NHANES 1999–2002 linked Medicare 
and mortality files till December 31, 2007. The associations between folate intake, 
folate biomarkers and the presence of UMFA and overall cancer incidence were 
assessed by Cox proportional hazards regression models. 
Results: With 8114 person-years of follow-up (median follow-up, 6.3 years), 128 
cancer cases were identified. After adjusting for confounders, higher levels of red 
blood cell (RBC) folate and higher intake of dietary folate equivalents were 





versus the reference group (the second quartile) of RBC folate and intake of dietary 
folate equivalents were 0.54 (95% CI: 0.31–0.93) and 0.54 (95% CI: 0.30–0.95), 
respectively. No significant associations between the presence of UMFA or intake of 
food folate and folic acid and cancer incidence were observed.  
Conclusion: High folate levels among older population appear to play a protective 




Folate is a general term for a group of water-soluble vitamins, which refers to 
various tetrahydrofolate derivatives naturally found i  foods. Folic acid is a synthetic 
form of folate used in dietary supplements and food fortification. During digestion, 
folic acid is reduced to biologically active forms which are identical to those from 
naturally occurring food folate. Folate (used as a collective term for naturally 
occurring folate and fortified/supplemented folic acid) is essential for numerous 
bodily functions. Since the human body does not have the ability to synthesize folate, 
a lack of sufficient dietary folate can lead to folate deficiency. This deficiency can 
result in many adverse health outcomes. The most notable one is neural tube defects 
(NTDs) in developing embryos. To reduce the incidence of NTDs, the U.S. 
government mandated folic acid fortification of enriched cereal-grain products in 
1998, which supplies on average an additional 100–2 µg folic acid per person per 
day based on the average American dietary pattern (117). The folic acid fortification 
has significantly reduced the prevalence of NTDs (2) and also improved the folate 





folate and red blood cell (RBC) folate concentrations increased by approximately 
100% and 55%, respectively, in post-fortification compared to pre-fortification years 
(1).  
Though the fortification policy has been successful in reducing the incidence 
of NTDs and improving folate status of the U.S. population, it also raises safety 
concerns that high folate intake may have adverse effects such as increasing cancer 
incidence. High intake of folate could promote the progression of pre-existing cancer 
by providing substrates for DNA replication in rapid cell division (14). Currently, 
about 11.3% of the U.S. population exceeds the Tolerab  Upper Intake Level (UL) of 
1mg/day, as an outcome of food fortification and supplement use (15). In some 
countries with folic acid fortification programs, hig  intakes of folate have been 
hypothesized to contribute to an increase in incidence of colon cancer (16, 22). The 
results of an ecological study of the U.S. and Canad  showed that the increase in 
incidence of colon cancer coincided with the increase in folate intake after mandatory 
folic acid fortification in these two countries (16). Similarly, an ecological study in 
Chile also found that an increased risk of colon cacer coincided with the folic acid 
fortification program (22). In addition, high dosage of folic acid supplementation 
(1,000 µg/d) was found to significantly increase th occurrence of multiple and 
advanced adenomas and total cancers among individuals with history of adenoma in a 
large clinical trial (14, 53). Another study showed that higher intake of folate from 
either supplemental folic acid (≥ 400 µg/d) or dietary folate intake (≥ 312 µg/d) was 





Moreover, the fact that unmetabolized folic acid (UMFA) has appeared in 
blood, as an outcome of high consumption of folic acid, may be of great public health 
interest. Unlike natural folate, folic acid used in dietary supplements or fortified foods 
needs to undergo reduction in the liver before participating in intracellular reactions. 
It is believed that as low as 200 µg of folic acid an saturate the enzyme dihydrofolate 
reductase (DHFR) which catalyzes folic acid to its reduced form, resulting in 
detectable unmetabolized folic acid in circulation (118). UMFA is reported to be 
prevalent in approximately 38% of U.S. adults aged ≥ 60 years, according to data of 
the National Health and Nutrition Examination Survey (NHANES) 2001–2002 (52). 
It was speculated that UMFA may be involved in the pathogenesis of cancer by 
disturbing cellular folate uptake and normal intracellular folate metabolism (10-12, 
53). However, the association between UMFA and cancer risk is yet unknown.  
We conducted a study to examine the associations between folate intake, 
folate biomarkers, and the presence of UMFA and overall cancer incidence among 
adults aged ≥ 57 years who participated in NHANES 1999–2002, using the linked 
Medicare and mortality data.  
 
Subjects and methods  
Baseline data for this study were obtained from NHANES 1999–2002. The 
NHANES is a nationally representative survey of the health and nutritional status of 
the non-institutionalized U.S. population, which uses a complex, multistage, 
probability sampling design. Each NHANES participant u dergoes a household 





38). The data of NHANES participants were subsequently li ked to longitudinal 
Medicare and mortality data (45, 48). More details bout NHANES and its methods 
can be found elsewhere (39).  
 
Medicare claims and mortality date linkage  
Data of NHANES 1999–2002 participants were linked to Medicare 
enrollment and claim records collected by the Centers for Medicare and Medicaid 
Services (CMS). The Medicare Chronic Condition File is a summary of clinical 
information extracted from the NCHS-CMS linked data, which includes the date of 
first occurrence for 21 chronic conditions, including colorectal, breast, prostate, lung 
and endometrial cancers from 1999 to 2007. Cancer (br ast, colorectal, prostate, lung 
and endometrial cancers) cases were identified using NCHS designed algorithms of 
disease codes from Medicare claim records. These are ICD-9 (International 
Classification of Disease), CPT-4 (Current Procedur Terminology) and/or HCPCS 
(Healthcare Common Procedure Coding System) codes. More details about 
algorithms of codes can be found in Appendix B of the NCHS-CMS Medicare 
Chronic Condition Summary File Data Dictionary (46).  
Data of NHANES 1999–2002 participants were also linked to the National 
Death Index (NDI) through December 31, 2006. The dat of death, underlying and 
multiple causes of death in ICD-10 were recorded in the Linked Mortality Restricted-
use File. More details about the linked Medicare file and Mortality file can be found 
elsewhere (45, 48). The Chronic Condition Summary File information is only 





2005 and 2007 (45). If participants were not alive by 2005, data on incidence of 
cancer of these participants were obtained from the NHANES Linked Mortality 
Restricted-use File.  
 
Cancer cases ascertainment  
Cancer cases were identified from the NHANES Linked Medicare or 
mortality files. For participants whose data were linked to the Medicare Chronic 
Condition summary file and who were alive between 2005 to 2007, cancer cases and 
date of first cancer occurrence between 1999 and 2007 were identified from the 
Summary File (46). For participants who died between 1999 and 2005, their Medicare 
claims data were not included in the Medicare Chronic Condition Summary File and 
cancer cases were identified from the Linked Mortality Restricted-use File. 
Underlying or multiple causes of death from cancer w e identified and date of death 
was used as the date of cancer occurrence.  
 
Study subjects 
We used data of NHANES 1999–2002 participants aged 57 years and over 
(n=3997) to capture all individuals who would potentially reach the age of Medicare 
eligibility by 2005 to 2007 (Medicare has age-based entitlement at 65 years of age). 
There were 3192 participants whose data were linked to the Medicare data and 130 
participants who died between 1999 and 2005. Data of Medicare beneficiaries who 
had been enrolled in managed care plans were excluded (n=1034) from the analysis, 





excluded if individuals had renal dysfunction (serum creatinine > 131 µmol/L in men 
and > 115 µmol/L in women, n=84), liver disease (serum alanine aminotransferase > 
40 units/L, n=182) or cancer (other than skin cancer, n=213) at baseline examination. 
We also excluded data of participants who had incomplete folate exposure 
measurements (dietary folate intake) or blood folate biomarkers (n=275) or 
incomplete physical exam information (n=109). The final analytic sample was 1425, 
which included 1384 individuals whose data were linked to the Medicare files and 41 
individuals with data linked to Mortality File.  
 
Assessment of diet and supplements 
Energy and nutrient intakes including dietary folate nd folic acid from 
fortified foods were estimated from a 24-hour dietary recall, which was administered 
to each participant by NHANES trained dietary intervi wers in the MEC. Data on 
dietary supplements were collected through the NHANES Dietary Supplement 
Questionnaire at the household interview. Participants were asked a series of 
questions about vitamin or mineral supplement use during the past 30 days. Detailed 
information about frequency of consumption, duration of use, and dosage were 
collected for each reported dietary supplement. The average daily folic acid intake 
from dietary supplements and from foods fortified with folic acid were summed to 
reflect total daily folic acid exposure. In our study, dietary folate equivalents (DFEs) 
were used as the measurement of total folate intake to account for the difference in 





calculated using the equation: DFEs (µg) = food folate (µg) + 1.7 × folic acid from 
fortified foods or supplements (µg) (119).  
 
Biochemical measurements 
RBC folate and serum folate concentrations were measur d with the Bio-Rad 
Laboratories "Quantaphase II Folate/vitamin B12" radio ssay from BioRad, Hercules, 
CA. UMFA concentrations were determined in NHANES 1999–2002 only for 
participants aged 60 years and over by using a revised affinity/ HPLC method with 
electrochemical (coulometric) detection. The lower limit of detection for UMFA was 
0.18 nmol/L and values below the level of detection were set to zero. Serum 
creatinine was measured based on the Jaffe reaction. Serum alanine aminotransferase 
(ALT) was measured using an enzymatic rate method. C mplete details and 
documentation for each of these methods are describd elsewhere (43, 44).  
 
Socio-demographic and lifestyle variables 
Individuals were classified by non-Hispanic white, non-Hispanic black and 
others (Mexican American, other Hispanic and other race/ethnicity). Educational 
attainment was categorized as less than high school, igh school graduate (received a 
high school or high school equivalency diploma) andgreater than high school. 
Physical activity level was self-reported as sedentary, light, and moderate or higher. 
Alcohol consumption was assessed as grams per day fom the 24-hour dietary recall. 
Cigarette smoking status was categorized as never, former and current. A nonsmoker 





lifetime; a former smoker was defined as a participant who had smoked ≥ 100 
cigarettes and was not smoking at the time of the interview; and a current smoker was 
defined as a participant who had smoked ≥ 100 cigarettes and was smoking at the 
time of interview. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared (kg/m2).  
 
Statistical analysis  
Baseline data from NHANES 1999–2002, incidence of cancer obtained from 
the Medicare Chronic Condition Summary File and mortality data obtained from the 
Linked Mortality Restricted-use File were merged into a single file at the National 
Center for Health Statistics-Research Data Center (NCHS-RDC) computer lab. 
Analyses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC) and p 
< 0.05 was considered statistically significant.  
UMFA measurements were categorized into detectable UMFA (UMFA+) and 
undetectable UMFA (UMFA-) categories. ANOVA for continuous variables and Chi-
squared tests for categorical variables were used to xamine associations between 
quartiles of folate biomarkers (serum folate and RBC folate), dietary folate intake 
(food folate, folic acid and dietary folate equivalents) and characteristics of survey 
participants.  
Cox proportional hazards regression models were used to xamine hazard 
ratios (HR) and 95% confidence intervals (95% CI) for incidence of cancer by 
quartiles of folate intake and blood biomarkers. The second quartile, which includes 





regression models. The follow-up period of participants in survival analyses was 
estimated from the time of baseline data collection o the endpoint (the earliest 
occurrence of any cancer: lung, prostate, breast, colorectal or endometrial cancers). 
People who were alive or died of other causes were c nsored at the end of the follow-
up period (December 31, 2007) or at the date of death.  
For each of the folate intake and biomarker variables, we conducted a 
multivariable Cox proportional hazards regression model adjusted for confounders. 
These confounders included age, gender, race/ethnicity, educational attainment, 
energy intake, BMI, physical activity, smoking status and alcohol intake. We also 
tested for possible linear association between variables of folate intake and 
biomarkers and the incidence of overall cancer using linear regression models. Serum 
folate, RBC folate, intakes of dietary folate, folic acid and dietary folate equivalents 
were logarithmically transformed, because these fiv folate exposure variables were 
not normally distributed. The proportional hazards as umption that there is no 
significant interaction between predictors and follow-up time was assessed, and no 
violation to this rule was found.  
 
Results 
With 8114 person-years of follow-up (median follow-up, 6.3 years), 128 
cancer cases were identified; four of these cases were identified from the mortality 
files using underlying or multiple causes of death. T e characteristics of the cohort by 
quartiles of RBC folate and dietary folate equivalents are summarized in Table 4. 1. 





with higher educational attainment, nonsmokers, and users of vitamin supplements. 
Participants who had higher intake of dietary folate equivalents tended to be non-
Hispanic white man, with higher educational attainme t, more physically active, 
former smokers, and users of vitamin supplements.  
Results from linear regression analyses showed that there were significant 
inverse association between both RBC and serum folate and risk of cancer incidence 
(p < 0.01) (Table 4. 2). Individuals whose RBC folate levels were in the fourth 
quartile (≥ 422.0 ng/ml) had a significantly lower cancer incidence, compared to the 
reference group (237.8–318.0 ng/ml): the adjusted HR was 0.54 (95% CI: 0.31–0.93). 
Although there was a linear association between serum folate levels and risk of 
cancer incidence, there were no associations by serum folate categories. The 
association between the highest serum folate category and risk of cancer incidence 
approached significance (HR: 0.59, 95% CI: 0.33–1.05). In addition, individuals with 
intake of dietary folate equivalents in the fourth quartile (≥ 836.4 µg/d) had 
significantly lower cancer incidence: the adjusted HR for those in the highest quartile 
relative to those in the reference group (291.6–<467.0 µg/d) was 0.54 (95% CI: 0.30–
0.95), but no significant linear association was oberved (Table 4. 2). There were no 
associations observed between intake of dietary folate, total folic acid or the presence 
of UMFA and risk of cancer incidence (data not shown). 
 
Discussion 
This study showed inverse linear associations between both RBC folate and 





folate was inversely associated with overall cancer incidence. There was also a 
significant association between the highest quartile of dietary folate equivalents and 
lower risk of incident cancer.  
Folate is an essential vitamin in the maintenance of normal DNA function. It 
is a cofactor in DNA synthesis, repair and methylation. Folate deficiency is 
considered a risk factor for cancer. Inadequate folate may increase cancer risk by 
disturbing the synthesis of thymidylate and purines (20, 21), which may cause uracil 
misincorporation into DNA. The uracil misincorporation may destabilize DNA and 
increase risk of malignancy. A deficiency in folate lso affects methylation of DNA, 
which in turn influences gene expression and triggers carcinogenesis (21). The 
mechanisms through which folate influences DNA function suggest dual effects of 
folate on cancer, whereby low folate concentrations could trigger cancer initiation, 
while excessive folate intake could promote more rapid cancer progression following 
onset by providing DNA synthesis substrates (112).  
Several epidemiological studies conducted in pre-fotification years in the 
U.S. suggest that low folate intake (< 200 µg/day) are associated with an increased 
risk of cancer incidence (58, 59, 62). In our study, we did not observe a higher cancer 
risk in the lowest quartile (< 292 µg/day) compared to the reference group which 
included the recommended daily intake value (400 µg/day). However, due to folic 
acid fortification, only about 10% of individuals had total folate intake less than 200 
µg per day in our study. The small number of individuals with lower intake of folate 





We found that individuals in the highest quartile of total folate intake tended 
to have a lower cancer risk. This finding does not support the hypothesis that 
fortification of enriched cereal-grain products with folic acid may increase the 
incidence of cancer. Safety concerns have been raised that high folate intake may 
promote carcinogenesis. Several studies have reported positive associations between 
high folate intake levels and cancer risk. In two ec logical studies, the increase in 
intake of folate due to folic acid fortification was found to parallel an increase in the 
incidence of colorectal cancer in the U.S., Canada (16) and Chile (22). In clinical 
trials, administration of folic acid supplementation (1000 mg/d) in patients with a 
history of adenoma was found to accelerate the growth f adenomas and increase the 
risk of cancer (53, 120). However, a recent meta-analysis which pooled data of 
around 50,000 participants in randomized clinical tri s found that folic acid 
supplementation did not significantly increase or decrease the incidence of site-
specific cancer during the first 5 years of treatment. The doses used in these trials 
were higher than the average amounts consumed due to folic acid fortification of 
enriched cereal-grain products (117).  
In addition, results of our study suggest linear inverse associations between 
both RBC and serum folate and risk of cancer incidence. A study conducted among 
NHANES participants in pre-fortification years (NHANES III 1988–1994) (121) also 
found an inverse association between serum folate of 3.0–4.3 ng/ml and cancer 
mortality, but not at lower levels. In our study, the lowest quartile of serum folate 
concentration was higher than the levels observed in their study and an inverse linear 





Finally, we did not find UMFA to be significantly associated with cancer risk. 
Folic acid, a synthetic form of folate, needs to be reduced to its biologically active 
form (tetrahydrofolate) by the enzyme dihydrofolate reductase (DHFR) before taking 
part in intracellular reactions. High intake of folic acid could saturate the enzyme and 
result in the buildup of UMFA in circulation (96). In post-fortification years, UMFA 
is reported to be prevalent in about 38% of U.S. adults aged ≥ 60 years due to high 
consumption of folic acid from dietary supplements and fortified foods (52). 
However, little is known about intracellular effects of UMFA. UMFA has been 
proposed to interrupt normal folate metabolism through several mechanisms, 
including inhibiting folate-dependent enzymes and interfering with DNA synthesis 
and methylenetetrahydrofolate reductase (MTHFR) (7-9). One study found that high 
blood UMFA concentration associated with decreased natural killer cell cytotoxicity 
among postmenopausal women (11). Our study showed no association between 
UMFA and the incidence of cancer. The absence of a relationship may be due to 
insufficient power to detect a significant association, as UMFA was only measured 
for participants aged 60 years and over in NHANES 1999–2002. Additionally, 
because not all participants had detected UMFA in the blood, we examined the 
association between the presence of UMFA rather than t e amount of UMFA and risk 
of cancer incidence. Further study on larger samples of population is needed to 
examine the possible dose-response association between UMFA and risk of cancer.  
A limitation of this study is that cancer cases were identified using algorithms 
of disease codes from medical claim records. Medicare laims data were collected for 





incomplete hospital coding. Therefore, health insurance claim records may not reflect 
precise disease occurrence (122, 123). However, the eliability in identifying cancer 
incidence has been verified by several studies (124, 5). Additionally, the strength 
of Medicare claims data are not subject to recall bi s. Another limitation of our study 
is that we used overall cancer morbidity as the healt  outcome because the number of 
site-specific cancer cases was too small. Folate may have different effects on the 
etiologies of different cancers. 
Additionally, the date of death from cancer was used as the date of cancer 
occurrence for individuals who died between 1999 and 2005 as morbidity data were 
not available on participants who died before 2005. However, only four cancer cases 
were identified through the mortality files and could not have much impact on the 
results. Finally, due to our exclusion criteria, the study sample is not nationally 
representative.  
In conclusion, our findings suggest that folate may h ve a protective role 
against cancer even at post-fortification levels. UMFA detected in serum was not 







Table 4. 1 Characteristics of NHANES 1999–2002 participants by quartiles of red blood cell (RBC) folate and intake 
of dietary folate equivalents1 
 RBC folate (ng/ml)  Dietary folate equivalents (µg/d) 
 Q1 Q2 Q3 Q4  Q1 Q2 Q3 Q4 










836.4 ≥ 836.4 
Characteristics2          
Days of follow up 2193 ± 39 2096 ± 42 2179 ± 39 2187 ± 40  2162 ± 45 2193 ± 41 2201 ± 40 2091 ± 33 
Age (year) 68.6 ± 0.4 69.2 ± 0.4 70.8 ± 0.5 71.2 ± 0.5  70.2 ± 0.5 69.7 ± 0.4 69.9 ± 0.5 69.6 ± 0.4 
Gender, man (%)  59.2 55.1 50.6 44.9  44.3 54.1 57.6 55.6 
Race/ethnicity (%)           
 Non-Hispanic white 41.4 55.2 69.1 75.4  49.3 56.9 63.5 71.1 
 Non-Hispanic black  29.6 15.4 8.9 5.3  21.1 16.2 12.0 10.1 
 Other race 29.0 29.4 22.1 19.3  29.6 26.9 24.5 18.9 
Education level (%)           
 < High school 54.1 48.7 33.2 32.5  55.1 45.6 36.5 31.1 
 High school  18.9 20.5 27.2 23.4  19.1 23.8 22.5 25.7 
> High school 26.9 30.8 39.5 44.2  25.8 30.6 41.0 43.2 
Smoking (%)          
 Current  24.0 14.9 12.3 10.5  21.2 18.1 10.3 11.8 
 Former  34.6 40.6 36.4 36.8  33.9 35.4 40.7 41.7 
 Never 41.4 44.5 51.3 52.6  44.9 46.5 49.0 46.5 
Physical activity (%)          
 Sedentary 29.0 31.1 25.8 29.5  35.5 30.3 27.9 24.9 
 Light 58.3 55.7 59.3 55.6  54.5 56.4 57.3 57.1 
 Moderate/high 12.7 13.2 14.9 14.9  9.7 13.1 15.0 18.1 
Alcohol intake (gm/d) 6.5 ± 1.2 6.5 ± 1.1 4.0 ± 0.7 4.5 ± 0.9  4.2 ± 0.6 5.9 ± 1.1 6.1 ± 1.1 5.2 ± 0.9 
BMI (kg/m 2) 27.6 ± 0.3 28.4 ± 0.3 28.1 ± 0.3 28.0 ± 0.3  28.3 ± 0.3 28.1 ± 0.3 28.0 ± 0.3 27.7 ± 0.3 
Total energy intake (kcal/d) 1730 ± 45 1797 ± 42 1807 ± 40 1760 ± 41  1186 ± 24 1725 ± 31 2044 ± 40 2111 ± 47 
Folic acid supplement, users 









1 Frequencies do not add up to 100% because of rounding and missing values.  
 2 Mean ± SE for continuous variables, and percentages for categorical variables presented by quartiles of RBC folate and 






Table 4. 2 Hazard ratios (HR) of overall cancer and 95% confidence intervals (95% CI) by quartiles of red blood 
cell (RBC) folate, serum folate and intake of dietary folate equivalents  
  Quartiles of folate levels 
p for 
trend2 
  Q1 Q2 Q3 Q4  
Red blood cell folate (ng/ml) < 237.8 237.8 –< 318.0 318.0 –< 422.0 ≥ 421.0  
     Number of all-cancer cases 38 39 27 20 
 









     
Serum folate (ng/ml) < 10.7 10.7 –< 15.6 15.6 –< 22.9 ≥ 22.9 
 
     Number of all-cancer cases 42 32 30 19 
 









     
Dietary folate equivalents (µg/d) < 291.6 291.6–< 467.0 467.0 –< 836.4 ≥ 836.4 
 
     Number of all-cancer cases 31 38 38 18 
 







1 Adjusted for age, gender, race/ethnicity, smoking status, alcohol intake, energy intake, educational att inment, physical 
activity and BMI.   
2 Test for trend were performed using linear regression models by including log-transformed RBC folate, s rum folate or 










C) Associations between folate levels and stroke morbidity among 




Background: Mandatory folic acid fortification of enriched cereal-grain products in 
the U.S. has significantly improved the folate status of the general population. Folate 
is hypothesized to have a protective effect against stroke by lowering homocysteine 
levels. Few population-based studies have examined the associations between folate 
intake, folate biomarkers and homocysteine and the risk of stroke incidence following 
fortification of enriched cereal-grain products with folic acid.  
Objective: The purpose of this study was to examine longitudinal associations 
between folate intake, folate biomarker levels and homocysteine levels and the 
incidence of stroke among older adults in post-fortification years.  
Methods: Data of participants of the National Health and Nutrition Examination 
Survey (NHANES) 1999–2002 aged ≥ 57 years were used as the baseline data for this 
study. Incidence of stroke was obtained from the NHA ES 1999–2002 linked 
Medicare and mortality files up to December 31, 2007. The associations of folate 
intake and biomarkers levels with the incidence of stroke were assessed by Cox 
proportional hazards regression models. 
Results: With 8129 person-years of follow-up (median follow up, 6.3 years), a total 
of 123 stroke cases were documented. Results showed that individuals with lower red 
blood cell (RBC) folate or serum folate tended to have a higher risk of stroke 
incidence. After adjusting for potential confounders including plasma homocysteine, 
the hazard ratios (HR) for individuals in the lowest quartile versus those in the second 





(95% CI: 1.33–4.24), respectively. Individuals with higher plasma homocysteine 
levels tended to have a higher risk of stroke. The adjusted HR for individuals in the 
highest quartile versus the second quartile of plasma homocysteine was 2.00 (95% 
CI: 1.14–3.53). No significant associations between intake of dietary folate 
equivalents, food folate or total folic acid intake and risk of stroke incidence were 
observed.  
Conclusion: This study suggests a protective role of folate, independent of 
homocysteine, against stroke. Maintenance of normal blood folate levels may be 
important for prevention of stroke in the U.S. population.   
 
Introduction 
Folate is considered a preventive factor against stroke because it is a major 
determinant of homocysteine levels (126, 127). Folate serves as a methyl donor for 
homocysteine remethylation to methionine. Deficient folate could lead to elevated 
homocysteine levels, which have been associated with an increased risk of 
atherosclerotic disease including stroke. A 25% higher than normal circulating 
homocysteine concentration has been associated with a 19% higher risk of stroke 
(26). Since folate can lower homocysteine levels and that homocysteine is positively 
associated with risk of atherosclerotic disease, it has been suggested that folic acid 
fortification of enriched cereal-grain products may contribute to prevention of stroke 
by lowering blood homocysteine concentrations. It was reported in an ecological 
study that a decline in stroke mortality paralleled the population-wide increase in 





years in the U.S. (17). However, it is unclear how much of the decline in deaths from 
stroke is due to reduced incidence of stroke. Many f ctors, such as the hospitalization 
rate of stroke patients, may also impact stroke mortality (17, 18). Studies, particularly 
prospective studies, are needed to elucidate the effects of the increase in folate 
biomarker levels on the risk of stroke incidence. 
In addition, folate itself could be an important factor in stroke prevention 
independent of blood homocysteine levels. Folate is considered an important factor in 
maintaining normal vasculature epithelial function. It functions as an antioxidant in 
reducing the oxidative stress on the vasculature (128), and could restore levels of 
nitric oxide, an important protective molecule in the vasculature (129). The protective 
role of folate independent of homocysteine on stroke has been supported in several 
epidemiological studies (27, 28). Low serum folate levels were independently 
associated with a significantly higher risk of stroke among Canadians aged ≥ 65 years 
(28). Additionally, lower plasma folate levels were found to be independently 
associated with a significantly higher risk of hemorrhagic stroke in the prospective 
study of the Northern Sweden Health and Disease Study Cohort (27). However, data 
are not available in post-fortification years in the U.S.  
This study was conducted to examine longitudinal associations between folate 
intake and biomarker levels and homocysteine levels and the risk of stroke incidence 
among older adults in post-fortification years, using data of NHANES 1999–2002 and 







Subjects and methods  
Study population  
Baseline data were obtained from NHANES 1999–2002. NHANES is a nationally 
representative survey of the health and nutritional st tus of the non-institutionalized 
U.S. population, and uses a complex, multistage, probability sampling design. Each 
NHANES participant undergoes a household interview and a physical examination in 
a Mobile Examination Center (MEC). Date of participants was subsequently linked to 
longitudinal Medicare claims and mortality data. More details about NHANES and its 
methods can be found elsewhere (37, 38, 45).  
 
Medicare and mortality data linkage  
Data of NHANES 1999–2002 participants were linked to Medicare 
enrollment and claim records collected by the Centers for Medicare and Medicaid 
Services (CMS). The Medicare Chronic Condition File is a summary of clinical 
information extracted from the NCHS-CMS linked data, which includes the date of 
first occurrence for 21 chronic conditions, including stroke from 1999 to 2007. Stroke 
(stroke/transient ischemic attack) cases were identified using NCHS designed 
algorithms of disease codes from Medicare claim records. These are ICD-9 
(International Classification of Disease), CPT-4 (Current Procedure Terminology) 
and/or HCPCS (Healthcare Common Procedure Coding System) codes. More details 
about algorithms of codes can be found in Appendix B of the NCHS-CMS Medicare 





Data of NHANES 1999–2002 participants were also linked to the National 
Death Index (NDI) through December 31, 2006. The dat of death, underlying and 
multiple causes of death in ICD-10 were recorded in the Linked Mortality Restricted-
use File. More details about the linked Medicare file and Mortality file can be found 
elsewhere (45, 48). The Chronic Condition Summary File information is only 
available for successfully matched NCHS survey participants who were alive between 
2005 and 2007 (45). If participants were not alive by 2005, data on incidence of 
stroke of these participants were obtained from the NHANES Linked Mortality 
Restricted-use File.  
 
Ascertainment of stroke cases  
Stroke cases were identified from the NHANES Linked Medicare Chronic 
Condition Summary File or Mortality Restricted-use File. For participants whose data 
were linked to the Medicare Chronic Condition Summary file and who were alive 
between 2005 and 2007, stroke cases and date of first stroke occurrence were 
identified from the Chronic Condition Summary File (46). However, if participants 
died before 2005, their Medicare claims data were not included in the Medicare 
Chronic Condition Summary File. For participants who died between 1999 and 2005, 
stroke cases were identified from the Linked Mortality Restricted-use File. 
Underlying or multiple causes of death from stroke were identified and date of death 







We used data of participants in NHANES 1999–2002 aged 57 years and over 
(n=3997) to capture all individuals who would potentially reach the age of Medicare 
eligibility by 2005 to 2007 (Medicare has age-based entitlement at 65 years of age). 
There were 3192 participants whose data were linked to the Medicare Chronic 
Condition Summary and 130 participants who died betwe n 1999 and 2005. Data of 
Medicare beneficiaries who had been enrolled in managed care plans were excluded 
(n=1034) from the analysis, because claims of these b n ficiaries were not collected 
by CMS. Data were also excluded if individuals had liver disease (serum alanine 
aminotransferase > 40 units/L, n=182), renal dysfunctio  (serum creatinine > 131 
µmol/L in men and > 115 µmol/L in women, n=84) or ca diovascular disease (n=468) 
at the baseline examination. We also excluded data of p rticipants who had 
incomplete folate exposure measurements (dietary folate intake) or folate biomarkers 
(serum or RBC folate) (n=199) or incomplete physical exam information (n=74). The 
final analyses were conducted with data on 1281 persons.  
 
Baseline Socio-demographic and Lifestyle Variables  
Individuals were classified as non-Hispanic white, non-Hispanic black and 
others (Mexican American, other Hispanic and other race/ethnicity). Educational 
attainment was categorized as less than high school, igh school graduate (received a 
high school or high school equivalency diploma) andgreater than high school. 
Physical activity level was self-reported as sedentary, light, and moderate or higher. 
Alcohol consumption was assessed as grams per day fom the 24-hour dietary recall. 





nonsmoker was defined as a participant who had never smoked ≥ 100 cigarettes 
during his/her lifetime; a former smoker was defined as a participant who had smoked 
≥ 100 cigarettes and was not smoking at the time of the interview; and a current 
smoker was defined as a participant who had smoked ≥ 100 cigarettes and was 
smoking at the time of interview. Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared (kg/m2).  
 
Assessment of diet and supplements 
Energy and nutrient intakes, including dietary folate nd folic acid from 
fortified foods, were estimated from a 24-hour dietary recall, which was administered 
to each participant by NHANES trained dietary intervi wers in the MEC. Data on 
dietary supplements were collected through the NHANES Dietary Supplement 
Questionnaire at the household interview. Participants were asked a series of 
questions about vitamin or mineral supplement use during the past 30 days. Detailed 
information about frequency of consumption frequency, duration of use, and dosage 
were collected for each reported dietary supplement. In our study, the average daily 
folic acid from supplemental sources and from fortiied foods was summed to reflect 
total daily folic acid exposure. Dietary folate equivalents (DFEs) were used as the 
measurement of total folate intake to account for the difference in the bioavailability 
of naturally occurring food folate and folic acid. DFEs were calculated using the 
equation: DFEs (µg) = food folate (µg) + 1.7 × folic acid from fortified foods or 






Biochemical measurements  
RBC and serum folate concentrations were measured with the Bio-Rad 
Laboratories "Quantaphase II Folate/vitamin B12" radio ssay from BioRad, Hercules, 
CA. Plasma homocysteine was measured by using a fluorescence polarization 
immunoassay reagent set from Abbott Homocysteine assay, Abbott Park, IL. Serum 
creatinine was measured based on the Jaffe reaction. Serum alanine aminotransferase 
(ALT) was measured using an enzymatic rate method. C mplete details and 
documentation for each of these methods are describd elsewhere (43, 44).  
 
Statistical Analyses  
Baseline data from NHANES 1999–2002 files, incidence of stroke obtained 
from the Linked Medicare Chronic Condition Summary File and mortality data 
obtained from Mortality Restricted-use File were merged into a single analytical file 
at the National Center for Health Statistics-Research Data Center (NCHS-RDC) 
computer lab. Data analyses were performed using SAS (version 9.2; SAS Institute 
Inc, Cary, NC) and p < 0.05 was considered statistically significant.  
ANOVA for continuous variables and Chi-squared tests for categorical 
variables were used to examine associations between baseline quartiles of folate 
biomarkers (serum folate and RBC folate), dietary folate intake (food folate, folic 
acid and dietary folate equivalents), plasma homocysteine levels and potential 
confounders. Cox proportional hazards regression models were used to determine 
hazard ratios (HR) and 95% confidence intervals (95% CI) for stroke incidence by 





levels. The second quartile, which includes recommended dietary allowance of folate, 
was used as the reference group in the regression models. Follow-up person-years of 
participants were estimated from the time of baseline data collection to the endpoint 
(the earliest occurrence of stroke). Participants who died of other causes during the 
follow-up or were alive till the end of follow up were censored at the date of death or 
at the end of the follow-up period (December 31, 2007). 
 For each of the folate intake and biomarkers variables of interest, we 
constructed a multivariable model adjusted for confou ders, which included age, 
gender, race/ethnicity, smoking status, alcohol intake, education, physical activity, 
BMI, total energy intake, serum total cholesterol and high-density lipoprotein (HDL). 
Tests for trend were performed using linear regression models including folate intake 
and biomarkers variables as continuous variables. In these linear regression models, 
serum folate, RBC folate, food folate, and folic acid and dietary folate equivalents 
were logarithmically transformed, because these fiv folate exposure variables were 
not normally distributed. In addition, we constructed multivariable models further 
adjusted for plasma homocysteine to test the associati ns of folate levels with stroke 
independent of plasma homocysteine. The proportional hazards assumption that 
between predictor does not interact with the follow-up time was tested and no 
violation to the rule was found.  
 
Results 
With 8129 person-years of follow-up (median follow up, 6.3 years), a total of 





files using cause of death. Baseline characteristics of participants by quartiles of 
serum folate and RBC folate concentrations are summarized in Table 4. 3. Individuals 
with higher RBC and serum folate concentrations tended to be non-Hispanic white 
women, with higher educational attainment, never smokers, users of vitamin 
supplements, and those with higher educational attainment. Individuals with RBC and 
serum folate in the lowest quartile tended to have higher plasma homocysteine as 
compared to those in the second quartile.  
As shown in Table 4. 4, the incidence of stroke was significantly higher 
among participants with RBC concentrations in the lowest quartile (< 239.08 ng/ml): 
the adjusted HR for those in this quartile relative o those in the second quartile 
(239.08–317.83 ng/ml) was 2.54 (95% CI: 1.40–4.62). After including plasma 
homocysteine in the regression model, the adjusted HR was slightly attenuated and 
remained statistically significant, the adjusted HRwas 2.45 (95% CI: 1.34–4.49). HR 
estimates for those in third and highest quartile of RBC folate concentration did not 
statistically significantly differ from 1.0. In addition, individuals whose serum folate 
levels were in the lowest quartile (< 10.9 ng/ml) had a significantly higher risk of 
stroke, as compared to those of the second quartile (10.9–15.6 ng/ml). The adjusted 
HR for those in lowest quartile relative to those in the second quartile was 2.43 (95% 
CI, 1.37–4.33). After including plasma homocysteine in the regression model, the 
adjusted HR was slightly attenuated but still significant: HR= 2.38 (95% CI: 1.34–
4.25) and the linear association also remained significa t (p= 0.03). HR estimates for 
those in third and highest quartile of serum folate concentration did not statistically 





the highest quartile had a higher risk of stroke as compared to those in the second 
quartile (Table 4. 4): the adjusted HR for those in the highest quartile (≥ 11.36 µg/ml) 




This study showed that lower serum and RBC folate and higher plasma 
homocysteine folate levels are associated with a significantly higher risk of stroke 
incidence.  
Our findings did not show a significantly lower incdence of stroke among 
individuals with circulating folate (serum and RBC folate) levels in the highest 
quartile. The preventive effects of folate against stroke are considered to be via its 
roles in lowering homocysteine levels. However, among individuals who are not 
folate-depleted, higher folate levels do not appear to be associated with a further 
reduction in homocysteine levels and in turn not associated with a further reduction in 
the incidence of stroke (130). Our results support such findings and suggest that high 
blood folate concentrations above a certain level may not have additional beneficial 
effects against stroke in post-fortification years.  
Furthermore, we observed that incidence of stroke was significantly higher 
among those with serum or RBC folate in the lowest quartile compared to those with 
circulating folate in the second quartile. Our findings support those of previous 
studies that lower folate biomarker may be a risk factor of stroke. 





a significantly higher risk of stroke among Canadians ged ≥ 65 years (28). In the 
U.S., a study conducted in the pre-fortification years also reported that low serum 
folate levels (≤ 4.1 ng/ml) were associated with an increased risk of ischemic stroke 
among participants of the first National Health and Nutrition Examination Survey 
Epidemiologic Follow-up Study (1975–1987) (131). In our study, the cutoff value of 
the lowest quartile of serum folate of our participants is 10.9 ng/ml, which is much 
higher than the lowest level of those two studies. These levels of serum folate, 
however, were still associated with a significant higher risk for stroke.  
In addition, our results also showed that an elevated blood homocysteine 
concentration is a predictor of stroke. Findings of me previous epidemiological 
studies (132-135), but not all, (136-139) suggested that elevated homocysteine levels 
are associated with an increased risk of atherosclerotic disease. Homocysteine can 
only be broken down through either the trans-sulfuration or the remethylation 
pathway. Folate serves as a methyl donor for homocysteine remethylation to 
methionine. (25). Therefore, folate is considered to play a protective role against 
stroke by reducing homocysteine levels. Folate itself, however, may be an 
independently risk factor of stroke.   
Our results showed a protective role of folate against stroke independent of 
blood homocysteine levels. After further adjusting for plasma homocysteine 
concentrations in multivariable regression models, the risk estimates for those with 
RBC or serum folate in the lowest quartiles relative to those with RBC or serum 
folate in the second quartiles were slightly attenuated and remained statistically 





its effects on blood homocysteine concentrations, against stroke. Mechanisms 
involved in the association between folate and stroke were examined in previous 
studies, but not yet fully established. It was repoted that plasma folate, as an 
antioxidant, plays an important role in reducing the oxidative stress on the vasculature 
(128). In addition, folate was found to be able to restore levels of nitric oxide, an 
important protective molecule in the vasculature (129).  
Finally, we did not find significant associations between intake of dietary 
folate and the risk of stroke incidence. Previous st dies have shown mixed results. In 
the Nurses’ Health Study, no association was found between folate intake and all 
strokes or stroke subtypes among women (140). However, in the Health Professionals 
Follow-up Study, a significant inverse association between food folate and ischemic 
stroke was observed among men (141). Similar inverse as ociations between food 
folate and ischemic stroke were also observed in the prospective NHANES I study 
and the Northern Sweden Health and Disease Cohort Study (27, 142). In a 
prospective nested case-control study, food folate intake was inversely related to 
hemorrhagic stroke but not ischemic stroke. It should be noted that none of these 
studies were conducted in post-fortification years, when dietary folate intake of the 
U.S. population significantly increased. Intake of dietary folate was almost doubled in 
post-fortification compared to pre-fortification years (143). We cannot exclude the 
possibility that the lack of associations between intake of dietary folate and incidence 
of stroke is due to insufficient statistical power to detect significance and, therefore, 





A limitation of this study is that stroke cases were identified using algorithms 
from medical claims records. Medicare claims data were collected for billing 
purposes, and not for epidemiological study. There could be biased or incomplete 
hospital coding. Therefore, health insurance claim records may not reflect precise 
disease occurrence (122, 123). However, the strength of these data is that Medicare 
claims data are not subject to recall bias. Another limitation is that the date of death 
from stroke was used as the date of first stroke occurrence for individuals who died 
before 2005. The Medicare Chronic Condition Summary File does not include data 
on stroke incidence of Medicare beneficiaries who died before 2005. Only two stroke 
cases, however, were identified from either underlying cause of death or multiple 
causes of death and would not have much impact on the estimation of follow-up 
person-years.  
In addition, due to lack of data on genetic polymorphisms, we did not adjust 
for genetic factors which may play important roles in the association between folate 
and stroke (such as MTHFR polymorphisms C677T and A1298C) (144). 
Additionally, our study only assessed the associations of folate with all-stroke risk but 
not with stroke subtypes (ischemic or hemorrhagic stroke). Folate, however, may 
unequally impact the risk of them (27, 141). Finally, the study sample is not 
nationally representative. Data included in this study were of participants in 
NHANES 1999–2002 that linked to Medicare files and not enrolled in managed care 
plans.  
In conclusion, adequate blood folate levels appear to have protective effects 





additional beneficial effects on stroke. Maintenance of normal blood folate levels may 






Table 4. 3 Characteristics of NHANES 1999–2002 participants by quartiles of red blood cell (RBC) folate and serum 
folate1 
 RBC folate (ng/ml)  Serum folate (ng/ml) 












22.5 ≥ 22.5 
Characteristics2          
Days of follow up 2165 ± 42 2233 ± 39 2163 ± 42 2191 ± 42  2084 ± 44 2261 ± 36 2191 ± 41 2212 ± 43 
Age (year) 68.2 ± 0.4 68.8 ± 0.5 70.4 ± 0.5 71.2 ± 0.5  68.4 ± 0.5 68.7 ± 0.5 69.2 ± 0.5 72.3 ± 0.5 
Gender, man (%)   60.7 52.3 47.1 38.1  61.8 57.0 43.6 36.8 
Race/ethnicity (%)           
 Non-Hispanic white 41.9 54.5 69.2 76.6  47.3 55.4 62.3 77.1 
 Non-Hispanic black  29.2 16.5 9.4 4.5  26.4 16.2 11.8 5.5 
 Other race/ethnicity  28.9 29.0 21.4 18.9  26.4 28.3 25.9 17.4 
Education level (%)           
 < High school 54.2 43.0 31.2 30.1  53.4 43.3 32.8 29.7 
 High school  17.5 21.3 28.3 22.4  17.6 21.3 26.9 24.2 
> High school 28.3 35.2 40.6 47.4  29.0 35.4 40.3 46.1 
Smoking (%)          
 Current  22.7 14.5 10.7 10.3  22.3 16.2 10.2 10.0 
 Former  34.4 42.9 38.0 32.0  38.5 41.1 39.3 29.4 
 Never 42.9 42.6 51.3 57.7  39.2 42.7 50.5 60.7 
Physical activity (%)          
 Sedentary 26.6 27.1 23.7 27.2  32.8 21.7 24.9 24.8 
 Light 60.7 57.7 61.0 58.0  55.7 61.5 55.7 64.2 
 Moderate/high  12.7 15.2 15.3 14.7  11.5 16.9 19.3 11.0 
Folic acid supplement, users 
(%) 8.5 16.2 41.0 69.0 
 
8.5 16.2 41.0 69.0 
Alcohol intake (gm/d) 6.4 ± 1.2 8.2 ± 1.3 4.5 ± 0.8 5.0 ± 1.0  7.6 ± 1.3 6.8 ± 1.2 5.1 ± 0.9 4.9 ± 1.1 
BMI (kg/m 2) 27.6 ± 0.3 28.2 ± 0.3 28.0 ± 0.3 27.7 ± 0.3  28.6 ± 0.4 28.3 ± 0.3 27.7 ± 0.3 26.8 ± 0.3 
Total energy intake (kcal/d) 1729 ± 45 1840 ± 48 1803 ± 42 1791 ± 45  1792 ± 46 1823 ± 47 1794 ± 45 1737 ± 42 
Total cholesterol (mg/dL) 213.7 ± 2.4 213.9 ±2.3 212.5 ±2.2 209.1 ±2.1  213.0 ±2.4 211.2 ± 2.3 210.5 ± 2.2 215.1 ± 2.1 
HDL-cholesterol (mg/dL) 52.5 ± 0.9 54.1 ± 1.0 53.4 ± 0.9 54.7 ± 1.0  51.1 ± 0.9 51.9 ± 0.8 55.1 ± 1.0 56.5 ± 1.0 
Plasma homocysteine 
(µg/ml) 11.4 ± 0.3 9.7 ± 0.2 9.3 ± 0.1 9.4 ± 0.2 
 
11.5 ± 0.2 9.9 ± 0.2 9.2 ± 0.2 9.3 ± 0.2 
1 Frequencies do not add up to 100% because of rounding and missing values. Q, quartile.  





Table 4. 4 Hazard ratios (HR) of stroke and 95% confidence intervals (95% CI) by quartiles of red blood cell (RBC) 
folate, serum folate and plasma homocysteine  




Q1 Q2 Q3 Q4  
Red blood cell folate (ng/ml) < 239.1 239.1–< 317.8 317.8 –< 413.6 ≥ 413.6  
    Number of stroke cases 41 18 27 32 
 
   Adjusted HR11 (95% CI) 2.54 (1.40–4.62) 1.0 1.46 (0.77–2.76) 1.49 (0.80–2.77) 0.05 
   Adjusted HR22 (95% CI) 2.45 (1.34–4.49) 1.0 1.49 (0.78–2.84) 1.49 (0.77-2.87) 0.05 
      
Serum folate (ng/ml) < 10.9 10.9 –< 15.6 15.6 –< 22.5 ≥ 22.5 
 
    Number of stroke cases 38 21 26 33 
 
   Adjusted HR11 (95% CI) 2.43 (1.37–4.33) 1.0 1.45 (0.78–2.68) 1.31 (0.71–2.39) 0.02 
   Adjusted HR22 (95% CI) 2.38 (1.33–4.24) 1.0 1.49 (0.80–2.77) 1.35 (0.74–2.50) 0.03 
 
Plasma homocysteine (µg/ml) < 7.6 
 
7.6 –< 9.3 
 
9.3 –< 11.4 
 
≥ 11.4 
    Number of stroke cases 22 24 28 45 
 
    Adjusted HR1(95% CI) 1.21 (0.64–2.28) 1.0 1.38 (0.76–2.49) 2.00 (1.14–3.53) 0.18 
1Adjusted for age, gender, race/ethnicity, smoking statu , alcohol intake, educational attainment, physical activity, BMI, 
total energy intake, serum total cholesterol and high-density lipoprotein (HDL).   
2 Further adjusted for plasma homocysteine concentrations.  
3 Test for trend were performed using linear regression models by including log-transformed RBC folate, s rum folate or 
plasma homocysteine levels as a continuous variable.  
 





D) Associations between folate biomarker levels and renal function 




Background: Levels of folate biomarker of the U.S. population significantly 
increased since folic acid fortification of enriched cereal-grain products in 1998. 
Since kidneys are highly involved in maintaining folate homeostasis, the effect of 
folic acid fortification may be affected by reduced ki ney function. However, it is 
unclear what the impact of reduced kidney function is on folate status.  
Objective: The purpose of this study was to investigate the associations of renal 
function with levels of serum folate, red blood cell (RBC) folate, and plasma 
homocysteine and the presence of serum unmetabolized folic acid (UMFA) in U.S. 
adults. 
Design: Data of participants of the National Health and Nutrition Examination 
Survey (NHANES) 1999–2002 aged ≥ 40 years were used in this study. Associations 
between levels of folate biomarkers and homocysteine and the presence of UMFA 
and three estimated glomerular filtration rate (eGFR) categories (< 60, 60–90 and ≥ 
90 mL/min/1.73 m2) were assessed using multivariable regression models, controlled 
for confounders. The Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula was used to estimate eGFR. 
Results: In men and women, RBC folate and plasma homocysteine l vels were 
significantly higher among individuals with eGFR < 60 ml/min/1.73 m2 compared 
with those with eGFR ≥ 90 ml/min/1.73 m2; serum folate levels were not significantly 





more likely to appear in the blood of individuals with eGFR < 60 ml/min/1.73 m2 
compared to those with GFR ≥ 90 ml/min/1.73 m2 (OR: 2.2, 95% CI: 1.2–4.0).  
Conclusion: Reduced renal function may be implicated in the increased blood folate 
concentrations. Until more information is available, caution should be taken in 
consumption of folic acid-enriched foods and folic acid supplements among 
individuals with renal insufficiency. 
 
Introduction 
Folate is a general term for a group of water-soluble vitamins, which refers to 
various tetrahydrofolate derivatives naturally found i  foods. The kidneys are highly 
involved in maintaining folate homeostasis. A significant amount of folate is filtered 
daily and the proximal renal tubular reabsorption of folate prevents extensive urinary 
excretion of folate (29). Folate receptors and other ransporters such as cubilin and 
megalin located on renal tubule are believed responible for folate reabsorption (30). 
Expression of folate transporters was down-regulated nd the uptake and utilization 
of folate by peripheral tissue and organs were decreased in rat models of chronic 
kidney disease (31). Absorption of folate by the small intestine was found to decrease 
in rat models of chronic kidney disease in another study (32). These changes in folate 
utilization and absorption may result in disturbance in homeostasis of folate.  
Folate biomarker levels of the U.S. population have significantly increased 
since folic acid fortification of enriched cereal-grain products in 1998. Mean serum 
folate and red blood cell (RBC) folate are estimated to have increased by 





pre-fortification years (1). In addition, about 11.3% of the U.S. population exceeds 
the Tolerable Upper Intake Level (UL) of 1 mg/day, by consuming fortified foods and 
dietary supplements (5, 15). It has been reported that unmetabolized folic acid 
(UMFA) was prevalent in approximately 38% of U.S. adults in 2001–2002 as an 
outcome of high folic acid consumption (145).  
The effect of folic acid fortification, however, may be different in individuals 
with renal dysfunction, given that reduced renal function may have an impact on 
folate homeostasis. Studying the association between kidney function and folate 
levels may be of public health significance because chronic kidney disease (CKD) is 
an increasing health concern that currently affects about 13% of the U.S. population 
(19). Additionally, altered folate status such as low folate levels have been considered 
as a risk factor for adverse health outcomes such as cancer (21, 64). Increased folate 
levels (13, 14, 16) and the presence of UMFA (10-12, 23) have also been associated 
with increased risk of diseases, such as cancer and cognitive impairment.  
To date, few studies examined the associations between renal function and 
folate status, and the findings are not conclusive (33-35). In addition, no study has 
examined the association between renal function and UMFA. Therefore, this study 
was undertaken to further understand the associations of renal function with folate 
biomarkers and UMFA using data from NHANES 1999–2002.  
 






The National Health and Nutrition Examination Survey (NHANES) is a 
nationally representative, cross-sectional survey of the health and nutritional status of 
non-institutionalized U.S. population. It uses a complex, multistage, probability 
sampling design. Each NHANES participant undergoes a household interview and a 
physical examination performed in a Mobile Examination Center (MEC). More 
details about NHANES and its methods can be found elsewhere (37-39).  
Data of NHANES 1999–2002 participants aged ≥ 40 years were used in this 
study (n= 6671). Data of individuals undergoing dialysis (n=30) or had liver disease 
(serum alanine aminotransferase > 40 units/L, n=516) were excluded. Also excluded 
were data of individuals with incomplete dietary information (n=872), folate 
biomarkers (n=318) or serum creatinine (n=46) measurements. This study was 
conducted with the data of 4889 persons. In addition, analysis was also conducted on 
a subsample of NHANES 1999–2002 participants aged ≥ 60 years who had a UMFA 
measurement (n=2419).  
 
Assessment of diet and supplements 
Energy and nutrient intakes, including dietary folate nd folic acid from 
fortified foods, were estimated from a 24-hour dietary recall, administered in the 
MEC. Data on dietary supplements were collected through the NHANES Dietary 
Supplement Questionnaire at the household interview. Participants were asked a 
series of questions about vitamin or mineral supplement use during the past 30 days. 
The average daily intake of folic acid from all dietary supplements was calculated 





day and the serving size unit from the product label (146). In our study, the average 
daily folic acid intake from dietary supplements and from foods fortified with folic 
acid were summed to reflect total daily folic acid exposure. Dietary folate equivalents 
(DFEs) were used as the measurement of total folate intake to account for difference 
in the bioavailability of naturally occurring food folate and folic acid. DFEs were 
calculated using the equation: DFEs (µg)= food folate (µg) + 1.7 × folic acid (µg) 
(119).  
 
Measures of blood biochemical and kidney function  
Serum folate and RBC folate concentrations were measur d with the Bio-Rad 
Laboratories "Quantaphase II Folate/vitamin B12" radio ssay from BioRad, Hercules, 
CA. UMFA concentrations were determined in NHANES 1999–2002 participants 
aged ≥ 60 years by using a revised affinity/ HPLC method with electrochemical 
(coulometric) detection. The level of detection for UMFA was 0.18 nmol/L and 
values below the level of detection were set to zer. Plasma homocysteine was 
measured by using a fluorescence polarization immunoassay reagent set from Abbott 
Homocysteine assay, Abbott Park, IL. Serum alanine aminotransferase was measured 
by using an enzymatic rate method. (42). Serum creatinine was measured based on 
the Jaffe reaction. Creatinine measurements of NHANES 1999–2000 were 
recalibrated to standardized creatinine measurement values (obtained at the Cleveland 
Clinic Research Laboratory, Cleveland, Ohio), using the equation: standard creatinine 
= 0.147+1.013 × uncalibrated serum creatinine (mg/dL) (147). Estimate glomerular 





Collaboration (CKD-EPI) creatinine formula (148). Complete details and 
documentation for each of these methods are describd elsewhere (43, 44).  
 
Baseline socio-demographic and lifestyle variables  
Individuals were classified by race/ethnicity as non-Hispanic white, non-
Hispanic black and others (Mexican American, other Hispanic and other 
race/ethnicity). Educational attainment was categorized as less than high school, high 
school graduate (received a high school or high school equivalency diploma) and 
greater than high school. Physical activity level was categorized as sedentary, light, 
and moderate or higher by using answers to the question “Average levels of physical 
activity each day” in the physical activity questionnaire. Alcohol consumption was 
assessed as grams per day from one 24-hour dietary r call. Cigarette smoking status 
was categorized as never, former and current. A nonsm ker was defined as a 
participant who had never smoked ≥ 100 cigarettes during his/her lifetime; a former 
smoker was defined as a participant who had smoked ≥ 100 cigarettes and was not 
smoking at the time of the interview; and a current smoker was defined as a 
participant who had smoked ≥ 100 cigarettes and was smoking at the time of inquiry. 
Body mass index (BMI) was calculated as weight in kilograms divided by height in 
meters squared (kg/m2).  
 
Statistical analyses:  
Data analyses were performed using SAS for windows (version 9.2, SAS 





Institute, Research Triangle Park, NC). Analyses were conducted incorporating the 
four-year sampling weight to adjust for complex study design (51). Individuals with 
eGFR less than 60 mL/min/1.73 m2 and those with eGFR between 60 and 90 
mL/min/1.73 m2 were defined as having reduced renal function and mil ly reduced 
renal function, respectively (50). Data of participants were classified into three 
categories according to their eGFR values (< 60, 60–90 and ≥ 90 mL/min/1.73 m2). 
UMFA measurements were categorized into detectable UMFA (UMFA+) and 
undetectable UMFA (UMFA-) categories. Serum folate nd plasma homocysteine 
levels were not normally distributed (with a skewness > 4), and, therefore, these two 
variables were log-transformed before group comparison and regression analyses. All 
tests were stratified by gender (men and women), and the eGFR ≥ 90 mL/min/1.73 m2 
category was set as the reference group. Statistical significance was set at p < 0.05. 
Dunnett's test and Chi-squared tests were used to compare group means of 
continuous variables and group percentages of categorical variables, respectively. 
Serum folate, RBC folate and plasma homocysteine lev ls were assessed in relation 
to eGFR using multivariable linear regression models. Regression models for serum 
folate and RBC folate were adjusted for age, gender, race/ethnicity, smoking status, 
alcohol intake, BMI, physical activity, educational attainment and intake of dietary 
folate equivalents. Regression model for plasma homocysteine was additionally 
adjusted for intake of vitamin B12. eGFR was also examined as a continuous variable 
in association with folate biomarkers and the associati n was represented as p for 
trend. In addition, we examined associations between UMFA and eGFR categories. 





intervals (95% CI) were estimated based on eGFR categories using multivariable 
logistic regression models. Logistic regression models were adjusted confounders, 
including age, gender, race/ethnicity, smoking status, alcohol intake, BMI, physical 
activity, educational attainment and intake of dietary folate equivalents.  
 
Results 
The mean age of the study population was 57.3 years, and 44.8% were men. 
Prevalence of individuals with eGFR < 60 mL/min/1.73 m2 was 10.9 %. Individuals 
with eGFR < 60 mL/min/1.73 m2 were more likely to be older, non-Hispanic white, 
nonsmokers (in women), former smokers (in men), less physically active, have lower 
educational attainment, and users of folic acid supplements (in women) (Table 4. 5). 
There was no significant difference in intake of dietary folate or vitamin B12 by 
eGFR categories.  
In both men and women, RBC folate levels were significantly higher in the 
eGFR < 60 mL/min/1.73 m2 group compared to reference group (p < 0.05), after
adjustment for age, gender, race/ethnicity, smoking status, alcohol intake, BMI, 
physical activity, educational attainment and intake of dietary folate equivalents 
(Table 4. 6). There were no significant differences in serum folate by categories of 
eGFR. Plasma homocysteine levels were significantly higher among participants in 
the eGFR < 60 and 60–90 mL/min/1.73 m2 category compared to the reference group 
(p < 0.001) after controlling for confounders including intake of vitamin B12 (Table 





significantly higher prevalence of UMFA compared to th se in the reference group 
(OR: 2.2, 95% CI: 1.2–4.0). 
 
Discussion 
Results of this study showed that reduced renal functio  as determined by 
eGFR was associated with higher RBC folate and plasma homocysteine levels among 
men and women, and higher prevalence of UMFA among women, as compared to 
individuals in the highest eGFR category. Additionall1y, even individuals in the 
intermediate eGFR category (60–90 mL/min/1.73 m2) had significantly higher plasma 
homocysteine levels as compared to those in the highest eGFR category.  
Results suggest that reduced renal function was associated with a higher RBC 
folate levels. RBC, which has a lifespan of 120 days, ccumulates folate only during 
erythropoiesis, the process by which the bone marrow pr duces red blood cells (149). 
Therefore, red blood cell folate concentrations respond slowly to changes in folate 
intake and are indicative of long-term folate status. RBC uptake of folate is believed 
to be through FBP (folate binding protein) (150) and RFC (reduced folate carrier) 
(151) transport systems. Expression of folate receptors including RFC was found to 
be down-regulated in peripheral tissues and organs including the small intestine, 
heart, liver and brain, in rat models of chronic kidney disease. Such down-regulation 
of folate receptors can result in reduced folate uptake and utilization of folate by 
peripheral tissues and organs (31). However, it is yet unknown what is the impact of 





Previous evidence suggests that RBC folate levels may not be affected 
significantly by renal insufficiency. Results of previous studies showed that folate 
levels could maintain normal without folate supplementation among individuals with 
renal insufficiency, even among those undergoing dialys s (153, 154). Additionally, it 
was reported in 1999 that RBC folate levels of over 80% of dialysis patients were 
within the normal range (155). Our findings indicate higher RBC folate levels among 
individuals with renal insufficiency. This association may be due to widely used folic 
acid supplements in individuals with renal insufficiency (156). However, the 
association between RBC folate and lower eGFR remained significant even after 
controlling for confounders including folic acid and dietary folate intakes.  
In addition, our results did not show any significant difference in serum folate 
concentrations between lower eGFR (eGFR < 90 mL/min/1.73 m2) versus the normal 
category. A few studies examined plasma or serum folate levels among chronic 
kidney disease patients but results were inconclusive. In one study among patients 
with chronic kidney disease receiving dialysis showed increased plasma folate levels 
(33), while other studies reported decreased serum folate concentrations among 
dialyzed patients (34, 35). The mechanism which leads to altered serum/plasma folate 
levels in individuals with renal insufficiency were examined but not fully established. 
It was reported that intestinal folate absorption was significantly reduced in a rat 
model of chronic kidney disease (32). Also, folate uptake and utilization of folate by 
peripheral organs and tissues was found reduced in a rat model of chronic kidney 





utilization by peripheral organs and tissues may possibly contribute to normal serum 
folate levels.  
Additionally, in our study individuals who had lower renal function (eGFR < 
90 mL/min/1.73 m2) were at increased risk of higher homocysteine levls. This result 
supports other studies, which showed that declining re al function is associated with 
elevated plasma homocysteine levels (157-160). A study by Bostom et al. showed 
that hyperhomocysteinemia was prevalent in 83% of patients with renal insufficiency 
(25). Nutrient deficiency, impaired renal excretion of homocysteine and disturbance 
of metabolism of amino acids required for breakdown f homocysteine are 
hypothesized to contribute to hyperhomocysteinemia among individuals with renal 
insufficiency (161, 162). However, the mechanisms through which renal insufficiency 
lead to elevated homocysteine levels have not been fully elucidated (157).  
Elevated homocysteine levels are usually found along with vitamin 
deficiency, especially folate deficiency, because folate serves as a methyl donor in the 
homocysteine remethylation pathway (25). However, in our study individuals with 
higher homocysteine concentrations, paradoxically, had higher RBC folate levels. 
One possible explanation for such findings may be that tissue uptake of folate is 
reduced in renal insufficiency (31). Intracellular inadequacy of folate may 
consequently lead to the accumulation of homocysteine. Another explanation may be 
that higher folate levels do not appear to further reduce homocysteine levels among 
individuals who are not folate-depleted (130). In our study, we found that individuals 
in the eGFR < 60 mL/min/1.73 m2 category had good nutritional status of folate 





possibly as an outcome of folic acid fortification. Therefore, high folate levels may 
coexist with elevated homocysteine levels in indiviuals with renal insufficiency.  
Finally, we found that UMFA was significantly more likely to appear in the 
blood of women with lower eGFR. Folic acid intake significantly increased after folic 
acid fortification of enriched cereal-grain products in 1998 and UMFA is reported to 
be prevalent among older adults aged ≥ 60 years (145). Folic acid needs to be reduced 
to its biologically active form before taking part in intracellular reactions. Excess 
intake of folic acid could bypass the conversion mechanism and lead to the 
appearance of UMFA in circulation (96). To date, little is known about the specific 
intracellular impacts of UMFA. It has been speculated, however, that UMFA may be 
associated with some adverse effects, including cognitive impairment in older 
population (12) and decreased immune function in postmenopausal women (11). The 
mechanism by which reduced eGFR might be associated wi h an increase in UMFA 
still remains to be studied.  
In summary, reduced renal function is associated with increased levels of 
RBC folate and plasma homocysteine. Reduced renal fu ction is also associated with 
the presence of UMFA in circulation among women. More studies are needed to 
understand the consequences of high intake of folic acid among people with reduced 
renal function and the health implications of high RBC folate. At this time, however, 
caution must be taken in consumption of folic acid-enriched foods and folic acid 






Table 4. 5 Baseline characteristics of NHANES 1999–2002 participants aged ≥ 40 years by eGFR categories1  
 eGFR (mL/min/1.73 m2) 
 All subjects < 60 60 –< 90 ≥ 90 
Men      
n 2332 328 1179 825 
Age    56.7 (0.3) 72.8 (0.9) ***3 58.9 (0.4) *** 49.8 (0.3) 
Race/ethnicity (%)       
 Non-Hispanic white 79.7 (76.1-82.8) 86.3 (83.1-89.1) *** 85.6 (82.0-88.7) *** 70.1 (65.0–74.7) 
 Non-Hispanic black  8.3 (6.6–10.3) 8.0 (5.4–11.6)* 6.0 (4.7–7.6)** 11.5 (8.9–14.7) 
 Other race/ethnicity 12.0 (9.0–15.9) 5.7 (2.9–11.1) *** 8.4 (5.7–12.2) *** 18.4 (14.2–23.6) 
Education level (%)       
 < High school 21.3 (18.8–24.2) 35.1 (28.0–42.8)* 18.2 (14.8–22.2) 22.2 (18.7–26.2) 
 High school  23.1 (20.3–26.2) 23.3 (17.3–30.7) 23.0 (20.5–25.6) 23.2 (18.8–28.3) 
 > High school 55.6 (51.6–59.5) 41.6 (32.2–51.8)* 58.8 (54.2–63.4) 54.6 (49.5–59.6) 
Smoking (%)     
 Current  21.9 (19.3–24.7) 12.6 (7.3–21.0) *** 16.6 (13.9–19.9) *** 31.1 (27.2–35.2) 
 Former  40.1 (37.5–42.8) 53.4 (47.1–59.6) *** 42.5 (38.5–46.6)** 33.7 (29.8–37.9) 
 Never 38.1 (34.8–41.5) 34.0 (29.2–39.2) 40.9 (36.0–46.0) 35.3 (31.2–39.6) 
Physical activity (%)     
 Sedentary 24.5 (22.0–27.2) 32.4 (25.8–39.7)** 27.8 (24.4–31.5)** 18.3 (15.5–21.3) 
 Light 49.4 (46.5–52.3) 51.8 (44.9–58.6) 49.1 (44.4–53.8) 49.3 (44.9–53.7) 
 Moderate/high 26.1 (23.4–28.9) 15.9 (11.6–21.3)*** 23.1 (20.0–26.5)** 32.5 (27.9–37.4) 
Alcohol intake (gm/d) 14.1 (1.0) 7.0 (1.7)** 13.6(1.1) 16.4(1.8) 
BMI (kg/m 2) 28.2 (0.2) 28.0 (0.3) 28.1 (0.2) 28.2 (0.3) 
Folic acid supplement user (%) 33.8 (31.1–36.6) 35.7 (29.5–42.4) 36.1 (32.2–40.1)* 30.3 (26.8–34.0) 
Dietary vitamin B12 (µg/d) 6.1 (0.3) 5.2 (0.4) 6.1 (0.3) 6.2 (0.6) 
Total dietary folic acid (µg/d)2 298.5 (9.2) 315.9 (22.2) 307.7 (11.9) 282.0 (11.9) 
Dietary folate equivalents (µg/d) 757.6 (17.4) 744.4 (41.1) 774.2 (22.5) 738.8 (23.1) 
     
Women      
n 2541 373 1117 1051 
Age    57.8 (0.4) 74.0 (1.0) *** 60.1 (0.7)*** 50.4 (0.4) 
Race/ethnicity (%)       
 Non-Hispanic white 76.6 (72.2–80.5) 83.0 (76.7–87.8) *** 84.1 (79.9–87.6) *** 66.2 (60.4–71.6) 
 Non-Hispanic black  9.4 (6.8–12.9) 8.1 (5.6–11.6)** 6.3 (4.2–9.3)* 13.4 (9.8–17.9) 
 Other race/ethnicity 14.0 (10.1–19.2) 8.9 (4.4–17.2) *** 9.6 (6.1–14.8) *** 20.4 (15.5–26.5) 





 < High school 23.8 (21.9–25.9) 37.7 (31.4–44.5)** 19.6 (16.1–23.5) 24.6 (21.8–27.6) 
 High school  25.5 (23.4–27.7) 29.7 (25.0–34.8)** 29.0 (26.0–32.2)** 20.3 (16.9–24.3) 
> High school 50.7 (48.1–53.3) 32.6 (26.4–39.5)*** 51.5 (47.4–55.6) 55.1 (50.6–59.5) 
Smoking (%)     
 Current  17.4 (15.2–19.8) 7.2 (4.5–11.2) *** 15.5 (12.7–18.7)** 22.5 (19.0–26.4) 
 Former  26.0 (23.1–29.1) 29.8 (23.6–37.0) 27.2 (23.5– 1.2) 23.5 (19.0–28.7) 
 Never 56.7 (53.7–60.0) 63.0 (56.8–68.8)** 57.4 (54.1–60.6) 54.0 (50.1–57.9) 
Physical activity (%)     
 Sedentary 29.0 (26.1–32.1) 37.4 (30.9–44.4) 27.2 (23.3–31.5) 28.6 (24.4–33.3) 
 Light 55.8 (52.8–58.6) 53.3 (46.5–60.0) 55.7 (51.5–60.0) 56.6 (51.7–61.3) 
 Moderate/high 15.2 (13.0–17.7) 9.3 (6.3–13.6)* 17.1 (14.0–20.8) 14.8 (12.3–17.7) 
Alcohol intake (gm/d) 5.2 (0.6) 1.9 (0.8)** 5.4 (0.8) 6.0 (0.9) 
BMI (kg/m 2) 28.5 (0.3) 28.7 (0.6) 28.4 (0.3) 28.6 (0.4) 
Folic acid supplement user (%) 41.1 (37.9–44.4) 44.5 (39.5–49.7)* 43.1 (38.5–47.9)* 37.8 (34.3–41.4) 
Dietary vitamin B12 (µg/d) 4.2 (0.2) 3.8 (0.3) 4.3 (0.3) 4.3 (0.3) 
Total dietary folic acid (µg/d)2 271.0 (7.4) 277.2 (20.5) 275.5 (10.3) 264.0 (11.4) 
Dietary folate equivalents (µg/d) 659.1 (14.0) 645.9 (36.4) 667.2 (17.8) 653.8 (24.0) 
1 All values are means and SEs or percentages and 95% CIs by eGFR categories.   
2 Total dietary folic acid represents the sum of dietary and supplemental folic acid consumption. 
3 Dunnett's test and Chi-squared test were used to test th  differences between eGFR categories for continuous variables 
and categorical variables, respectively. Difference between the eGFR categories and the reference group is statistically 

























Table 4. 6 Red blood cell (RBC) and serum and folate, plasma homocysteine levels and prevalence of unmetabolized 
folic acid (UMFA) of NHANES 1999–2002 participants aged ≥ 40 years by eGFR categories1 
 eGFR (mL/min/1.73 m2) 
 < 60 60 –< 90 ≥ 90 p for trend3 
Men     
    RBC folate (ng/ml) 361.2 (16.4)* 324.6.5 (6.9) 314.9 (5.0) 0.02 
    Serum folate (ng/ml)2 2.6 (0.03) 2.6 (0.02) 2.6 (0.02) 0.19 
    Plasma homocysteine (µmol/L)2 2.5 (0.03)*** 2.3 (0.01)*** 2.2 (0.02) < 0.001 
    UMFA+ (%) 4 28.8 (22.0–36.8) 25.3 (20.8–30.3) 30.9 (21.3–42.6) -- 
        Odds ratio5  0.7 (0.4–1.5) 0.7 (0.4–1.2) 1.0 -- 
Women     
    RBC folate (ng/ml) 373.3 (12.4)* 339.0 (5.1) 333.1 (5.0) 0.21 
    Serum folate (ng/ml)2 2.7 (0.05) 2.7 (0.02) 2.7 (0.02) 0.34 
    Plasma homocysteine (µmol/L)2 2.4 (0.03)*** 2.1 (0.01)*** 2.0 (0.01) < 0.001 
    UMFA+ (%) 4 35.7 (30.1–41.7) 31.5 (25.3–38.3) 21.0 (14.6–29.4) -- 
        Odds ratio5  2.2 (1.2–4.0) 1.7 (0.9–3.0) 1.0 -- 
     
1 All values, except odds ratios, are least square means and SEs or percentages and 95% CIs by eGFR categories.   
2Significance levels were obtained at the log-transformed scales of variables. Group comparisons of folate biomarkers were 
performed adjusted for age, gender, race/ethnicity, smoking status, alcohol intake, BMI, physical activity, educational 
attainment and dietary folate equivalents. Group comparisons of plasma homocysteine were also adjusted from dietary 
vitamin B12. * and *** , difference between eGFR category and the referenc group (eGFR ≥ 90 mL/min/1.73 m2) was 
statistically significant at p < 0.05 and p < 0.001, respectively. 
3 Test for trend were performed using linear regression models by including eGFR as a continuous variable.  
4 Analyses for UMFA were performed on a subsample (n=2419) of NHANES 1999–2002 participants aged ≥ 60 years who 
had UMFA measurements 
5 Odds ratios and 95% CIs for the presence of UMFA in blood based on eGFR categories. The eGFR ≥ 90 mL/min/1.73 m2 






Chapter 5: Summary and Implications 
 
A) Summary 
Fortification of enriched cereal-grain products with folic acid has significantly 
improved the nutritional status of folate of the general population in the U.S. 
However, there are safety concerns regarding high intake of folate particularly among 
older adults, who consume high levels of cereals and dietary supplements containing 
folic acid. High levels of folate biomarkers may disturb folate metabolism and results 
in unintended health consequences. Furthermore, there ar  still some gaps in our 
knowledge of folate metabolism. Therefore, studies are needed to address these safety 
concerns and knowledge gaps. In this dissertation, we first examined what we know 
of the key events and control points in the metabolic pathway of folate. We then 
examined the effects of folate intake and biomarkers on the incidence of cancer, 
stroke and cardiovascular disease. Finally we looked at the potential association 
between renal insufficiency and the levels of folate biomarkers.  
In the study cohort of older adults (≥ 57 years) from NHANES 1999–2002, a 
total of 128 cancer and 123 stroke cases were identified from the linked Medicare 
claims data with an average 6.3 years of follow-up.  
Folate was found to have a protective effect against cancer. The highest levels 
of RBC folate and intake of dietary folate equivalents were associated with a 
significantly lower risk of cancer incidence. No significant associations between 
UMFA, serum folate and cancer risk were observed. We also observed that lower 
serum folate and RBC folate levels were associated with a higher risk of stroke and 





No significant associations between risk of stroke incidence and intake of dietary 
folate equivalents, food folate and total folic acid were observed. Finally, we did not 
find significant associations between folate intake nd biomarkers and incidence of 
CVD. 
Additional analyses were conducted to examine the impact of reduced renal 
function found in relatively large segments of the U.S. population and folate status. 
The results showed that renal insufficiency was associated with increased RBC folate 
and plasma homocysteine levels. RBC folate and plasma homocysteine levels were 
significantly higher in individuals with reduced renal function, compared to those 
with normal renal function, after adjustment for potential confounders. Among 
women but not in men, UMFA was significantly more like y to appear in the blood of 
individuals with reduced renal function compared to th se with normal renal function.  
The strength of this study is that we obtained datafrom the NHANES, which 
has information on health and nutrition status collected on a large sample of the U.S. 
population and these data are linked to Medicare and mortality follow-up data. 
Incidence of cancer, stroke and CVD were extracted from these linked files, which 
are not subject to recall bias. However, the results are not representative of the U.S. 
population because Medicare data was not available on all older participants because 
some of them chose managed care health insurance and their claims data are not 
collected by CMS.  
Despite the large NHANES dataset, participants’ follow-up was on average 
about 6 years, so cancer outcomes were on a small sample and we could not examine 





relationship between renal function and folate levels could be established because the 
data used were from the cross-sectional NHANES survey. 
 
B) Implications 
In addition to the U.S., 52 countries mandated fortification of enriched cereal-
grain products with folic acid and more countries are discussing initiating folic acid 
fortification (164). Discussion of the benefits and safety concerns regarding possible 
harmful consequences of this fortification program require careful and continued 
monitoring of its effects especially in vulnerable populations, such as older 
population and individuals with renal insufficiency. Additionally, a petition was 
presented to the Food and Drug Administration to extend folate fortification to corn 
masa flour to target the Hispanic population which has not benefited as much in the 
decline in NTDs from folic acid fortification (165). Before additional fortification of 
food with folic acid, further studies must be conducted.  
Results of this study do not show additional negative impact on cancer, stroke 
and CVD. But these are not definitive results and more studies are required. 
Additionally, for some subpopulation, such as those with renal insufficiency, it is 
important to examine the implication of much higher levels of folate biomarkers and 
until more information becomes available, caution must be taken in consumption of 
folic acid enriched foods and folic acid supplements among this subpopulation.  
Future investigation of the association between UMFA and chronic disease in 
a larger study sample is needed. The hypothesis has been raised that UMFA is 





the balance of folate and several folate-dependent enzymes (10-12, 53). This 
disturbance may consequently result in increased risk of certain diseases, such as 
cancer. Even if it is biologically plausible, the effect of chronic exposure to UMFA is 
not conclusive in population-based studies. Until the impact of UMFA on health is 
fully understood, UMFA might be used as a biomarker for monitoring folic acid 
exposures.   
Further studies are also needed to assess the effects o  high intake of folate on 
cancer particularly among high-risk subpopulations in post-fortification years. Folate 
plays essential roles in DNA synthesis and repair. Adequate folate is considered an 
important protective factor against cancer. However, the timing of folate supplement 
administration also could affect how and whether folate promotes cancer progress. 
High folate intake could promote the development of carcinogenesis after the onset of 
cancer. The population group targeted by folic acid fortification is women of 
childbearing age. However, individuals with existing cancer or pre-cancerous 
conditions also consume foods enriched with folic acid. It is essential to determine if 
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